Podcasts about CNS

MAPS BOGO: https://mapsbogo.com Buy one get one free — mix and match any of the top 10 most popular programs (Anabolic, Aesthetic, Performance, 15 Minutes, Anywhere, Symmetry, Starter, Muscle Mommy, Powerlift, 40+) for $157.   In this episode the guys break down whether a good gym actually makes a difference — covering convenience, cleanliness, and culture as the three things the gym industry has identified as the real drivers of consistency. They cover why 24 Hour Fitness put gyms within ten miles of each other on purpose, why culture matters more than equipment, why CrossFit proved that a grimy box with no air conditioning can beat a fully equipped luxury gym, and why the right culture depends entirely on where you are in your fitness journey. They also get into new probiotic research showing measurable effects on strength, endurance and fat loss through improved amino acid availability, gut wall permeability in athletes, and CNS firing efficiency, why gluten sensitivity is more common than people realize and how to know if it's affecting your results, the famous Nun Study from the 1980s showing nuns with full Alzheimer's pathology who still scored perfectly on cognitive tests, why their voices have all gotten lower over ten years of podcasting, and the new Mind Pump Hormones community on Skool replacing their Facebook forum. Then they answer questions from Instagram.   MP Hormones Skool Community (free): https://skool.com/mindpumphormones Moderated peptide and hormone therapy discussion with medical professionals.   SPONSORS   Seed Daily Synbiotic: https://seed.com/mindpump Code: 25MINDPUMP for 25% off your first month. Probiotics discussed on air — emerging data on strength gains, endurance and fat loss through gut health optimization.   Hiya (kids' multivitamin): https://hiyahealth.com/MINDPUMP 50% off first order. Zero sugar, non-GMO, vegan, allergy-free. The only kids multivitamin the guys recommend.   LINKS   Mind Pump Store: https://mindpumpstore.com Maps Fitness Products: https://mapsfitnessproducts.com Instagram: @mindpumpmedia   0:00 - Intro 1:46 - Does a good gym actually make a difference? 8:48 - The three things that predict gym consistency: convenience, cleanliness and culture 11:06 - Why CrossFit proved culture beats equipment every time 17:43 - Why the right culture depends on where you are in your journey 23:12 - Why Orange Theory consistency is worth celebrating before evolving 27:27 - New probiotic research showing measurable effects on strength, endurance and fat loss 31:05 - Leaky gut is more common in athletes than the general public — why 34:10 - How gluten sensitivity shows up as low-level systemic inflammation without you realizing it 45:32 - The famous Nun Study — brains full of Alzheimer's pathology, perfect cognitive scores 59:34 - Mind Pump Hormones community is moving from Facebook to Skool 1:02:20 - Q&A: How to progress in a squat when you're already strong and in a deficit 1:05:04 - Q&A: Traditional sauna vs. infrared — which one has the science behind it? 1:08:13 - Q&A: If muscles grow through rest, how do bodybuilders train 6-7 times a week? 1:12:55 - Q&A: How long should you give a calorie deficit before expecting to see results?

“The microbiome world is moving from supplementation towards ecosystem restoration.” - Danielle ArnoldFor a long time, the functional medicine approach to gut health focused on getting rid of what shouldn't be there. It was all about finding the overgrowth, using antimicrobials, adding probiotics, and rebuilding. Those tools are still useful, but our understanding of the microbiome has become much more sophisticated. Now, we can think about restoring the gut's ecosystem, including the keystone species that help create an environment where beneficial bacteria can thrive, and opportunistic bacteria have a much harder time taking over.With the complex clients we see as women's health practitioners, this shift becomes especially important. Someone with endometriosis, histamine intolerance, MCAS, long COVID, metabolic dysfunction, or significant digestive symptoms may not be able to jump straight into eating 45 grams of fiber a day. Sometimes we have to work in a very specific order, supporting digestion, reducing overgrowth, rebuilding beneficial species, and then gradually giving those microbes the fibers and polyphenols they need. The goal is not simply a better stool test. It's a more resilient gut ecosystem that can better support the immune system, nervous system, hormone health, and the rest of the body.In today's episode, I'm joined by Dr. Oscar Coetzee and Danielle Arnold, CNS, from Designs for Health for a wonderfully nerdy conversation about what we now know about rebuilding the gut microbiome. We talk about new research on keystone species like Akkermansia, Faecalibacterium, and Roseburia, how these microbes work together, when antimicrobials may still be useful, why the order of treatment matters for sensitive clients, histamine and hormone health, H. pylori, digestive function, fiber and polyphenols, stool testing, how better gut microbiome support can become part of our clinical thinking, and more.Enjoy the episode, and let's innovate and integrate together!---Learn more or watch the video version of this conversation at https://integrativewomenshealthinstitute.com/how-to-rebuild-a-healthy-gut-microbiome-with-dr-oscar-coetzee-and-danielle-arnold/.Connect with me and access our entire platform at IntegrativeWomensHealthInstitute.com (https://integrativewomenshealthinstitute.com/).Find and follow us @integrativewomenshealth on YouTube (https://www.youtube.com/@integrativewomenshealth) and Instagram (https://www.instagram.com/integrativewomenshealth/).

"They're really worried that radiation is going to be painful. So they come in for that first day of treatment very anxious. With our patients with brain cancer, we're using the masks on the table, and those masks are very tight and hold their heads very, very still. So they'll be very worried about being claustrophobic. We may start out the first day or two with a little bit of [lorazepam]. And they'll come to me and they'll say, 'This really hasn't been as bad as I thought it was going to be,'" ONS member Catherine McCluskey, BSN, RN, OCN®, ROCN™, radiation oncology staff nurse at Atrium Health Wake Forest Baptist in Winston-Salem, NC, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, who was the manager of oncology nursing practice at ONS at the time of the recording, during a conversation about radiation side effects in central nervous system (CNS) cancers. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by August 21, 2027. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to the side effects of radiation to treat CNS cancer. Episode Notes  Complete this evaluation for free NCPD.  ONS Podcast™ episodes: Radiation Site-Specific Side Effects series Episode 306: Cancer Symptom Management Basics: CNS Toxicities ONS Voice articles: Augmented Reality Simulations Reduce Patient Anxiety by Teaching Them About Radiation Therapy CNS Survivorship Needs More Research, Funding, and Training, Expert Panel Says Here's What the Updated CTCAE Version 6.0 Means for Oncology Nurses Highly Localized, Precision Radiation Therapies Require Nurses to Drive Care Coordination, Patient Education Hyperbaric Oxygen Therapy Shows Promise for Certain Radiation Side Effects ONS book: Manual for Radiation Oncology Nursing Practice and Education (fifth edition) ONS courses: Indications of Targeted Radiotherapy to the Brain and Spine: 2025 ONS Congress® Session ONS ROCN™ Certification Review™ ONS/ONCC® Radiation Therapy Certificate™ Supporting Radiation Side Effect Management Through ONS Evidence-Based Resources: 2025 ONS Congress® Session Clinical Journal of Oncology Nursing articles: Implementing a Standardized Educational Tool for Patients With Brain Tumors Undergoing Concurrent Temozolomide and Radiation Therapy Radiation Necrosis: A Differential Diagnosis Dilemma The Neurocognitive Late Effects of Cranial Radiation Therapy: The Often-Unrecognized Outcomes Oncology Nursing Forum article: Symptom Clusters in Patients With Brain Tumors Undergoing Proton Beam Therapy ONS Huddle Cards: External Beam Radiation Proton Therapy Proton Therapy Radiation ONS Guidelines™ and Symptom Management Resources Cognitive impairment Fatigue Mucositis Radiodermatitis ONCC resources: Big List of CE Radiation Oncology Certified Nurse (ROCN™) Common Terminology Criteria for Adverse Events (CTCAE v6.0) Patient Health Questionnaire (PHQ-9 and PHQ-2) To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "With primary tumors—glioblastomas, astrocytoma, all of those types of cancerous primary CNS tumors, the tumors are not very well-defined. They have little tentacles that kind of go out, so doing something like Gamma Knife, which is very precise, is not as effective as an external beam because the external beam will deliver radiation to all those little tentacles that are out there in the brain. And with Gamma Knife, you really can't effectively do that." TS 2:34 "When we're doing radiation to the brain, fortunately there aren't that many acute toxicities involved. Sometimes they'll have some mild dermatitis. Usually, it's not very significant. They, like everyone else who gets radiation, will have fatigue. Usually once we get to the end of the second week of radiation, into the third week for our patients with primary CNS tumors—the hair loss—they'll start to notice hair loss just in the treatment area. But those are typical, the things that we've seen most. Sometimes we'll have patients who will experience some nausea, maybe a few headaches, but really the acute toxicities are not severe typically with our patients with brain tumors." TS 8:30 "[For] the fatigue, I tell patients to just listen to their bodies. We don't want them to be sedentary, and we want them to go out and continue living their lives. But I do warn them that the fatigue is pretty much common to all patients receiving radiation at various degrees, depending on the patient. I just tell them to do what they feel like doing, and then when they're tired to rest, and if they find themselves having a nap in the afternoon, that's okay." TS 13:51 "What I find with these patients in particular is that a lot of times, their first symptoms related to any type of cancer are CNS symptoms from brain metastasis. Our patients with lung cancer or melanoma—they come in through the emergency room for altered mental status or seizures or something like that. They find a mass in their brain, and then they find a mass on their lung, or they find masses everywhere. Typically, they want to treat the brain masses first before they start them on any kind of systemic treatment. And so, they'll come to us, and they're in shock. Everything's happened very quickly. They haven't had a chance to really catch their breath. They're overwhelmed. And so I try to make sure they understand that everyone that they see here is part of their team and is with them through this journey and they're not alone." TS 25:36 "A couple of years ago, ONS put out an email asking for people to volunteer to do a delineation study about the feasibility of doing a radiation oncology certified nursing exam. And I, just on a whim, responded to that email. It's not something I've ever done before, and thinking that I would not be put on the team. … And I thought, 'I don't have enough experience, I don't know what I'm doing, and they won't choose me.' And lo and behold, they put me on this role delineation study. … I have met so many incredible nurses with all kinds of experience. I've learned so much. It has opened up a lot of things for me and it's been really exciting, so all I can do is say take advantage of those opportunities when they come. Don't think that you don't know enough, because you know more than you think you do." TS 32:38 

Listen Online: About this episode: The First Lady of Nutrition welcomes renowned natural health and Ayurveda expert Dr. John Douillard to uncover what thousands of years of ancient wisdom can teach us about living longer, and why modern science is finally beginning to catch up. From the three Ayurvedic body types (Vata, Pitta, and Kapha) to eating with the seasons and working with your natural circadian rhythm, Dr. Douillard explains why some of the smartest longevity “hacks” may not be new at all. Ann Louise and Dr. Douillard also dive into some of today's hottest health topics, including why revving up metabolism later in life may backfire, his concerns about peptides for people with a history of cancer, and why less may be more when it comes to melatonin. Plus, discover the surprising longevity connection between your lymphatic system, nitric oxide, and something most of us do roughly 20,000 times a day: breathe. Dr. Douillard explains why breathing through your nose instead of your mouth can make such a difference—and why he even teaches some of his patients to sleep with their mouths taped shut. Dr. John Douillard, DC, CAP, is a globally recognized leader in natural health, Ayurveda, and sports medicine who has spent decades exploring the science behind ancient healing traditions and translating that wisdom into practical strategies for modern health and longevity. For more information check out LifeSpa.com.The post Ancient Wisdom, Modern Science: Biohacking Longevity with Ayurveda first appeared on Ann Louise Gittleman, PhD, CNS.

Diesen Dienstag: Rauch und Feinstaub aus dem Waldbrand im Hohen Venn belasten Luxemburg weiterhin und können je nach Wetterlage auch in den kommenden Tagen noch spürbar sein. Das extreme Niedrigwasser auf dem Rhein trifft Luxemburgs Wirtschaft: Schiffe können nur noch einen Bruchteil ihrer normalen Ladung transportieren, wodurch Logistik und Lieferketten teurer werden. Die Ärztevereinigung AMMD und die CNS haben sich nicht auf eine neue Konvention geeinigt – trotzdem sollen Konsultationen und Erstattungen für Versicherte zunächst unverändert weiterlaufen. ­ ­Hier geht‘s zum letzten Pendler-Update: Wieder mehr deutsche Grenzgänger, Zugausfälle & neue Index-Prognose ­Schon gehört? Grenzgänger gesucht: Zieht Luxemburg noch immer Deutsche an? ­ Schreibt uns eure Fragen und Anregungen gerne an pendler@wort.lu! ­ Der Pendler Club ist ein Podcast vom Luxemburger Wort. Mediahuis Luxembourg sind Teil des internationalen Trust Project, das für transparenten und vertrauenswürdigen Journalismus steht. Weitere Informationen dazu gibt es hier. ­ Moderation und Produktion: Jil Reale Redaktion: Luxemburger WortSee omnystudio.com/listener for privacy information.

In Part 2 of Tara's conversation with Dr. Lindsey Berkson, they continue the discussion by looking at the different forms and delivery methods of HRT, including Bi-Est, estradiol, estriol and progesterone. They discuss why the way a hormone is delivered can matter, why vaginal progesterone may work differently from oral or topical progesterone, and why individual response matters when choosing a delivery method. The conversation then moves into testosterone and breast health, including the role of hormone metabolites and estrogen receptors. Dr. Berkson also shares her thoughts on mammograms and breast cancer screening, including her own experience of finding breast cancer shortly after receiving a negative mammogram. This episode ultimately comes back to one of the biggest themes of the entire conversation: don't blindly follow a protocol simply because it's considered standard. Understand the evidence, understand the limitations, and make informed decisions with appropriate medical support.   In Part 2: Why Tara switched to an estradiol patch Dr. Berkson's history developing menopause supplements Progesterone, puberty and menstrual health Why hormone education is missing from conventional medical training Why Bi-Est? Bringing estradiol and estriol back into the conversation Testosterone, muscle, brain health and breast health Why progesterone delivery needs to be individualised Oral vs vaginal vs topical progesterone How Dr. Berkson approaches mammograms, ultrasound and other screening methods The breast cancer Dr. Berkson discovered after a negative mammogram Why Dr. Berkson created Everything Breast Cancer and her personal mission to help women navigate breast cancer Dr. Lindsey Berkson Lindsey Berkson, MA, DC, CNS, DACBN was a Distinguished Hormone Scholar at the Center for Bioenvironmental Research (CBR: Tulane/Xavier Universities). She is a leading figure in integrative medicine, renowned for her expertise in hormones, nutrition, digestion, and environmental science. With a background as a clinician, professor, bestselling author, and radio show host, she brings a wealth of experience to her work. At the CBR, she collaborated with pioneers in estrogen and sex-steroid receptor research. Dr. Berkson is also a respected educator, teaching MDs and pharmacists in advanced certification courses. She has developed innovative nutraceuticals, holds patents in bioidentical hormone therapy, and has contributed to groundbreaking research on dialysis/pharmaceutical medications and nutrition. Dr. Berkson consults internationally, focusing on medical nutrition for breast cancer, inflammatory bowel disease, renal problems, and complex health issues. Dr. B's Links: Email - admin@drlindseyberkson.com Webpage - www.drlindseyberkson.com Memberships - www.drlindseyberkson.com/membership Agile Thinking Substack - https://drlindseyberkson.substack.com/ Biotics Products - https://drlindseyberkson.com/bioticsproducts/ Hormones: Vilified to Vindicated (Course) - https://drlindseyberkson.com/v2v/ Oxytocin Medicine - https://drlindseyberkson.com/oxytocinmedicine/ **Get $100 off Dr. Berkson's Everything Breast Cancer and/or Everything Hormones Courses by using the code: PC100TARA https://drlindseyberkson.com/everythingbreastcancer/ https://drlindseyberkson.com/everything-breast-cancer-nonprofessional/ https://drlindseyberkson.com/everythinghormones/ Estradiol vs. Bi-Est Debate, watch here: https://www.youtube.com/watch?v=u-p82VW1weA&t=2508s Watch Tara's Instagram Live with Dr. Berkson here: https://www.instagram.com/reel/DN6ieQRE0PI/   Fix Your Gut Masterclass Stop Blaming the Food! The Real Reason You've Still Got Bloating and Pooping Problems and How to Fix Your Gut for Good. In this free, live masterclass Tara will walk you through the real reason your gut symptoms keep coming back, no matter what you've tried, and what actually needs to happen to fix them properly, at the root, for good. [Save your spot HERE]  

Wéi reagéieren d'Salariatsvertrieder an der Gesondheetskeess op d'Ukënnegung vun der AMMD, keng nei Konventioun mat der CNS wëllen ze ënnerschreiwen?

Does estrogen really cause breast cancer? It's one of the biggest fears women have when considering HRT, and in this conversation, Dr. Lindsey Berkson takes Tara back to where much of that fear began. They unpack the history of the Women's Health Initiative, how the original messaging around hormones shaped medical practice, and what later analyses of the research have shown. Dr. Berkson explains why she believes estrogen has been misunderstood, including the difference between estrogen's effects on different receptors and why "estrogen-positive" breast cancer does not necessarily mean estrogen caused the cancer. They also discuss research involving women with ER-positive breast cancer who received estrogen and what those studies reported. Dr. Berkson then shares her own breast cancer story and why it ultimately led her to spend decades researching hormones. This is a fascinating conversation about how medical messaging evolves, why women need to understand the details behind the studies, and why Tara believes these are conversations women deserve to have. In Part 1:  The history of the Women's Health Initiative and why it was created What the early research was actually showing about estrogen and breast cancer The controversial press release that changed the conversation around HRT What 20 years of reanalysis of the Women's Health Initiative revealed Oral vs topical vs vaginal estrogen: why delivery method matters Tara's experience with vaginal progesterone and sleep/anxiety The controversy surrounding oral progesterone The debate around estriol What "estrogen-positive" breast cancer actually means The theory behind estrogen and progesterone fueling breast tumors   Dr. Lindsey Berkson Lindsey Berkson, MA, DC, CNS, DACBN was a Distinguished Hormone Scholar at the Center for Bioenvironmental Research (CBR: Tulane/Xavier Universities). She is a leading figure in integrative medicine, renowned for her expertise in hormones, nutrition, digestion, and environmental science. With a background as a clinician, professor, bestselling author, and radio show host, she brings a wealth of experience to her work. At the CBR, she collaborated with pioneers in estrogen and sex-steroid receptor research. Dr. Berkson is also a respected educator, teaching MDs and pharmacists in advanced certification courses. She has developed innovative nutraceuticals, holds patents in bioidentical hormone therapy, and has contributed to groundbreaking research on dialysis/pharmaceutical medications and nutrition. Dr. Berkson consults internationally, focusing on medical nutrition for breast cancer, inflammatory bowel disease, renal problems, and complex health issues. Dr. B's Links: Email - admin@drlindseyberkson.com Webpage - www.drlindseyberkson.com Memberships - www.drlindseyberkson.com/membership Agile Thinking Substack - https://drlindseyberkson.substack.com/ Biotics Products - https://drlindseyberkson.com/bioticsproducts/ Hormones: Vilified to Vindicated (Course) - https://drlindseyberkson.com/v2v/ Oxytocin Medicine - https://drlindseyberkson.com/oxytocinmedicine/ **Get $100 off Dr. Berkson's Everything Breast Cancer and/or Everything Hormones Courses by using the code: PC100TARA https://drlindseyberkson.com/everythingbreastcancer/ https://drlindseyberkson.com/everything-breast-cancer-nonprofessional/ https://drlindseyberkson.com/everythinghormones/ Estradiol vs. Bi-Est Debate, watch here: https://www.youtube.com/watch?v=u-p82VW1weA&t=2508s Watch Tara's Instagram Live with Dr. Berkson here: https://www.instagram.com/reel/DN6ieQRE0PI/   Fix Your Gut Masterclass Stop Blaming the Food! The Real Reason You've Still Got Bloating and Pooping Problems and How to Fix Your Gut for Good. In this free, live masterclass Tara will walk you through the real reason your gut symptoms keep coming back, no matter what you've tried, and what actually needs to happen to fix them properly, at the root, for good. [Save your spot HERE]  

Den AMMD-President reagéiert am Wort op déi gescheitert Mediatioun mat der CNS a mécht sech drop gefaasst, vun CNS a Gewerkschaften duerch den Dreck gezunn ze ginn

Join Dr. Clancy  and his guests, Drs. Ganesan and Mangala, as they discuss what is known about the microbiome, its relation to disease and how we can promote a healthy microbiome. Episode Transcript CE Credit Available Host: Gerard Clancy, MD Senior Associate Dean for External Affairs Professor of Psychiatry and Emergency Medicine University of Iowa Carver College of Medicine Guests: Sukirth Ganesan, DDS, PhD, MPH Centennial Research Associate Professor Director of the Advanced Education Program in Periodontics University of Iowa College of Denistry and Dental Clinics Ashutosh Mangalam, PhD Professor of Pathology Interdisciplinary Graduate Program in Molecular Medicine University of Iowa Carver College of Medicine Financial Disclosures:  Dr. Gerard Clancy, his guests, and Rounding@IOWA planning committee members have disclosed no relevant financial relationships. Nurse: The University of Iowa Roy J. and Lucille A. Carver College of Medicine designates this activity for a maximum of 1.00 ANCC contact hour. Physician: The University of Iowa Roy J. and Lucille A. Carver College of Medicine designates this enduring material for a maximum of 1.00 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Other Health Care Providers: A certificate of completion will be available after successful completion of the course. (It is the responsibility of licensees to determine if this continuing education activity meets the requirements of their professional licensure board.) References/Resources:  Shahi SK, Ghimire S, Jensen SN, Lehman PC, Rux AG, Sinha S, Borcherding N, Tanas MR, Gibson-Corley KN, Ganesan SM, Karandikar NJ, Mangalam AK. IL-17A deficiency in HLA-DR3 transgenic mice enriches beneficial Prevotella species in gut to promote Tregs and reduce CNS autoimmunity. Microbiome. 2026 Jun 29;14(1):176. doi: 10.1186/s40168-026-02394-w. PMID: 42374500 Lehman PC, Ghimire S, Price JD, Ramer-Tait AE, Mangalam AK. (2023) Diet-microbiome-immune interplay in multiple sclerosis: Understanding the impact of phytoestrogen metabolizing gut bacteria. Eur J Immunol. Nov; 53(11):e2250236. DOI: 10.1002/eji.202250236. PMID: 37673213. Mendoza-Leon MJ, Mangalam AK, Regaldiz A, Gonzalez-Madrid E, Rangel-Ramirez MA, Alvarez-Mardonez OA, Vallejos OP, Mendez C, Bueno SM, Melo-Gonzalez F, Duarte Y, Opazo MC, Kalergis AM, Riedel CA. (2023) Gut microbiota short-chain fatty acids and their impact on the host thyroid function and diseases. Front Endocrinol (Lausanne). Jun 30; 14:1192216. DOI: 10.3389/fendo.2023.119226. PMID: 37455925. PMCID: PMC10349397.

D'AMMD wäert keng Konventioun mat der CNS ënnerschreiwen, dozou ginn et Kommentaren an den Zeitungen, an och iwwer d'Ofwaasserproblemer beim Minett-Kompost

Broadcast from KSQD, Santa Cruz on 8-06-2026: >ul> An emailer with persistent nine-month nerve damage in her right leg after a hysterectomy asks whether peptides could help. Dr. Dawn attributes the injury to lithotomy positioning during surgery, then reviews the main nerve-regeneration candidates in the FDA peptide review pipeline: BPC-157 (Body Protection Compound, strong rat data on sciatic nerve recovery with thicker myelin sheaths), intracellular sigma peptide (targets glial scar CSPGs blocking CNS regrowth), C3 peptide 156-181, GHK-Cu (copper peptide, upregulates nerve growth factor and neurotrophin-3), self-assembling hydrogel scaffolds for bridging nerve gaps, ARA-290/cibinetide (an erythropoietin fragment with early small fiber neuropathy trial data), and Semax (used internationally for stroke rehab). She adds standard functional-medicine adjuncts: alpha-lipoic acid, methylated B12, and methylfolate at high doses for six months. An emailer asks about safe features when buying an infrared sauna. Dr. Dawn covers three concerns: EMF exposure (look for shielded/grounded heaters testing under 1 milligauss at seat level, avoid unshielded Wi-Fi and Bluetooth panels); VOC off-gassing (avoid plywood, particle board, and MDF because of formaldehyde and benzene release, and avoid Western red cedar and pine because of high terpene emissions and instead choose poplar, basswood, or eucalyptus); and avoid built-in oxygen ionizers, which produce ozone as a coronal-discharge byproduct that irritates airways and generates secondary oxygenated VOCs. Dr. Dawn covers the surprisingly long list of medications that raise estrogen in middle-aged men—including nearly all antidepressants and antiepileptics, statins, NSAIDs (specifically naproxen and indomethacin but not ibuprofen), most blood pressure medications, PPIs, H2 blockers, Parkinson's drugs, antihistamines, and muscle relaxants. She recommends annual monitoring of the estrogen-to-testosterone ratio and offers rebalancing options: topical chrysin (blocks aromatization), indole-3-carbinol, calcium D-glucarate (blocks enterohepatic estrogen recirculation), soy (competitive receptor inhibition), and grape skin extract. The first mRNA-based flu vaccine was approved this week for adults 50 and over. Beyond the 27% improvement in seasonal efficacy over conventional shots, the strategic advantage is manufacturing speed. This will be critical when or if bird flu mutates to respiratory human transmission. Since mRNA vaccine can be reprogrammed from a new viral sequence in weeks versus the three-to-four-month growth cycle for conventional flu vaccines, rapid response can save lives. But mRNA vaccine side effects include more injection-site pain and fatigue - more like a tetanus shot than a traditional flu shot.. A Spanish prospective study of chemicals affected puberty in the young studied 500 girls followed from ages 7-10 and again at 14-16 used urine chemical measurements as objective exposure markers rather than food diaries. Ethylenethiourea, a metabolite of dithiocarbamate fungicides used heavily on strawberriess,was associated with earlier menarche, while a chlorpyrifos metabolite was associated with delayed menarche. this latter effect was more pronounced in overweight girls whose fat tissue concentrated the compound. Dr. Dawn recommends organic strawberries and keeping children away from fumigated fields. University of Pennsylvania School of Dental Medicine researchers developed a chewing gum from lablab beans containing the natural antiviral protein FRIL, which reduced oral HPV by up to 93% in samples from head and neck squamous cell carcinoma patients. The gum also suppressed Fusobacterium nucleatum and Porphyromonas gingivalis, oral bacteria that promote cancer recurrence. Michigan State University's Hamburger lab studying delphinium (larkspur) alkaloids joined forces with Tomáš Pluskal's Czech Academy of Sciences lab studying wolfsbane (monkshood) after meeting at a Barcelona conference. Together they mapped the biosynthetic assembly line for aconite—an alkaloid with valuable applications against malaria, pain, cancer, and agricultural pests but impossibly slow to extract from source plants—and cloned the pathway into tobacco, which grows aggressively and produces large quantities of the compound. An emailer named in the message asks about an incidentally-discovered enlarged aorta on CT. Dr. Dawn notes it officially becomes an aneurysm at 4 cm (annual monitoring) or 5 cm (six-month monitoring), with smoking cessation critical since tobacco directly weakens the aortic wall. She describes the "zipper of fire" back pain of dissection versus catastrophic rupture, and notes Medicare covers a one-time screening ultrasound for ever-smokers over 65.

In this episode, Jennifer Venator, MSN, RN, CNS, CNOR, CRNFA, Executive Director, Surgical Services, Providence St. Jude Medical Center in Fullerton CA, shares how trusted, real-time data is improving surgical access, operational efficiency, and collaboration across care teams. She also discusses how automation and emerging AI capabilities can streamline perioperative workflows, reduce administrative burden, and help clinicians stay focused on patient care.

Are you tired of conflicting nutrition advice on social media? One day potatoes are "bad," the next day avocados are the problem. In this episode, we cut through the noise and explain why healthy eating doesn't have to be so complicated, and why intuitive eating makes so much sense. Why extreme diet trends are doing more harm than good The truth about intuitive eating and whole foods How social media influencers create confusion around nutrition Why sugar cravings and food addictions are more complex than willpower Simple strategies to build healthier eating habits that actually last Why meeting people where they are leads to sustainable lifestyle change How cooking at home and shopping for real food can transform your health Dr. Terri is joined by Elizabeth DiMeo, MS, CNS, LDN, Director of Education and Clinical Nutritionist at EVEXIAS Health Solutions. A Certified Nutrition Specialist and Licensed Dietitian Nutritionist with 25 years in clinical practice — and a former chef — Elizabeth has spent her career translating nutrition science for both practitioners and patients. She's also the person who will tell you, without apology, that a potato roasted in olive oil with chives and grass-fed butter is not the enemy. This conversation started as a rant about Instagram and turned into something more useful: an honest look at what "intuitive eating" actually means, why restriction culture has made people afraid of real food, and how clinicians should actually counsel someone who wants to change — not with a list of things to quit, but with things to add. Along the way: the three-day food log that reveals everything, the patient drinking six Big Gulps a day who became migraine-free, what cravings are really signaling, and how reference ranges quietly normalized a metabolic epidemic. If you're overwhelmed by conflicting food advice, tired of being told everything you enjoy is killing you, or you're a clinician trying to help patients who won't follow a perfect plan — this one's for you. What you'll discover in this episode: [00:57] / 00;07;22 — The Instagram post that set this whole conversation off, and what it gets backwards about fat [05:38] / 00;12;03 — What intuitive eating actually means — and how it got confused with hedonistic eating [09:47] / 00;16;12 — Paleolithic man didn't just eat meat: why the carnivore framing misreads history [14:26] / 00;20;51 — Meeting people where they are: nutrition advice that works on a real budget [16:14] / 00;22;39 — The three-day food log, what patterns it reveals, and why shame has no place in it [20:19] / 00;26;44 — Cheese, rennet, and the serving size almost nobody is actually eating [23:56] / 00;30;21 — Add before you subtract: the counseling approach that makes change stick [24:39] / 00;31;04 — Six Big Gulps a day, chronic migraines, and a year-long taper that worked [29:05] / 00;35;30 — Cravings as nutrient deficiency: pica, ice chewing, and what salt is really telling you [31:11] / 00;37;36 — How shifting lab reference ranges quietly normalized fatty liver and elevated fasting insulin [41:54] / 00;48;19 — "If you can't pick it, pull it, or kill it" — the simplest food rule in the episode [48:03] / 00;54;28 — Farmers markets, teaching kids to cook, and making whole food a family habit Food was never supposed to be this complicated. The Dr. Terri Show is presented by EVEXIAS Health Solutions. EVEXIAS Health Solutions is an emerging leader in integrative medicine on a mission to positively impact people's lives through the transformation of health care. EVEXIAS educates and trains practitioners on new, innovative, integrative therapies that support a preventative care model that drives vitality as you age. Learn more and find a provider near you at https://www.evexias.com Connect with Dr. Terri:

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into recent transformative events that are shaping this dynamic industry, from strategic mergers to groundbreaking drug approvals. Starting with the merger between Supernus Pharmaceuticals and Indivior Pharmaceuticals, this all-stock deal valued at $2.2 billion is set to create a powerhouse focused on central nervous system (CNS) disorders. By combining their resources, the new entity is expected to enhance its capabilities in neurological disorders with a robust portfolio of approved drugs. This merger allows the companies to leverage economies of scale, optimize research and development, and expand their market presence, offering promising prospects for advancements in treating CNS-related conditions. In regulatory news, Novartis has secured FDA approval for an expanded indication of Pluvicto (lutetium vipivotide tetraxetan), a radioligand therapy originally approved for PSMA-positive metastatic castration-resistant prostate cancer. This therapy can now be used for metastatic hormone-sensitive prostate cancer, marking a significant step forward in prostate cancer treatment. By targeting prostate-specific membrane antigen (PSMA) with precision, Pluvicto offers the potential for improved patient outcomes and highlights the growing role of radioligand therapies in oncology. Globally, Pharmamar's Zepzelca (lurbinectedin) has been approved in Canada, Qatar, and South Korea as a first-line maintenance therapy for extensive-stage small cell lung cancer. This approval signifies a potential shift in how aggressive cancer types are treated, particularly when combined with PD-L1 inhibitors, opening new avenues for effective combination therapies. Industry partnerships continue to drive innovation, as seen with Fujifilm and Taiho Pharmaceutical's collaboration to develop next-generation antibody-drug conjugate (ADC) manufacturing technologies using the Aralinq platform. With ADCs becoming increasingly pivotal in targeted cancer therapies due to their precision in delivering cytotoxic drugs to tumor cells, advancements in manufacturing could significantly enhance production capabilities and therapeutic efficacy. Financial dynamics within the industry remain robust. AbbVie has raised its 2026 revenue forecast to $67.6 billion, citing strong performances from its immunology drugs Skyrizi and Rinvoq. These therapies have shown substantial success in treating autoimmune conditions, reflecting their impact on AbbVie's financial health and reinforcing confidence in their commercial viability. On the clinical trial front, Ratio Therapeutics has successfully closed a $70 million Series C funding round to support its radiotherapeutics pipeline and initiate the ATLAS trial. This infusion of funds underscores the continued interest and investment in radiopharmaceuticals with promising applications in oncology. The landscape of mergers and acquisitions remains active as AstraZeneca and Bristol Myers Squibb reportedly engage in early-stage merger discussions. Such a merger could create an oncology giant valued at approximately $400 billion, potentially reshaping competitive dynamics and accelerating innovation across therapeutic areas. Regulatory changes are also underway with HRSA advancing a revised 340B rebate model pilot program despite hospital opposition. The implications for healthcare providers are significant as this could affect operational efficiencies and financial strategies within participating entities. Overall, these developments reflect ongoing trends toward industry consolidation and strategic partnerships that foster innovation in drug manufacturing technologies. Regulatory approvals continue to advance precision medicine through targeted therapies, showcasing the sector's dynamic nature as it addresses unmet medical needs while navigating complex regulatory environments. Meanwhile, Sandoz's settlement of nearly $500 million for antitrust claims in the U.S. highlights ongoing scrutiny of industry competition practices. This settlement signals potential shifts in market dynamics as companies seek to resolve legal challenges while maintaining operational integrity. Cybersecurity has emerged as a critical concern following Amgen's reported breach compromising sensitive patient data. This incident amplifies the need for enhanced data protection measures to safeguard information integral to patient trust and competitive integrity. In leadership news, BioNTech has appointed Guido Oelkers as CEO amid its continued innovation in mRNA technology post-COVID-19. This strategic move underscores BioNTech's commitment to leadership capable of navigating advances in mRNA therapeutics. Lastly, Novo Nordisk faced setbacks with its investigational therapy ziltivekimab failing a phase 3 trial targeting inflammatory pathways for cardiovascular outcomes. Despite such challenges, these high-stakes trials highlight both risks and opportunities inherent in pharmaceutical innovation. As we reflect on these stories, it's clear that scientific advancements, regulatory developments, and strategic business moves continue to shape the trajectory of the pharmaceutical and biotech sectors. These efforts promise significant implications for future drug development and patient care as companies strive to harness breakthroughs while adapting to evolving industry landscapes.Support the show

>p>Broadcast from KSQD, Santa Cruz on 7-30-2026: A type of coffee brewed from beans that have been altered by passage through the digestive track of civet cats is a delicacy in Southeast Asia. A Scientific Reports paper using gas chromatography analyzed Kopi Luwak (civet-processed coffee beans) versus fresh-picked beans, finding elevated caprylic and capric acids that carry the characteristic flavor notes found in dairy products. Dr. Manuel Esteller sampled and tested the blood, saliva, urine, and stool of the oldest human Maria Branyas Morera, who died last year at 117. Despite exceptionally short telomeres, she carried anti-inflammatory genetic variants seen in long-lived dogs, worms, and flies, and had unusually high Bifidobacterium levels—likely boosted by her three-daily-servings-of-yogurt habit. Dr. Dawn defends sunscreen use against Environmental Working Group scare campaigns, noting that concerns about absorption of sunscreen ingredients into blood remain theoretical while sunburn's melanoma link is well-established. She argues that a badly sunburned toddler starts a clock that can produce melanoma by the late teens. The FDA advisory committee is reviewing certain short amino acid chains popularly known as "peptides" for potential compounding-pharmacy production, covering proposed to treat ulcerative colitis, wound healing, insomnia, insulin resistance, migraines, and osteoporosis. Dr. Dawn flags that five to seven committee members have industry conflicts of interest, but argues that even flawed approval is preferable to the current gray market, where analysis shows vials contain only 4-28% of labeled content along with endotoxin and toluene contamination. She proposes surveillance tracking of prescribed peptides to catch adverse effects early, citing a foreign melanocortin nasal spray tanning product that caused rare nasal melanomas as a cautionary example. Utah State biochemists working with the Cas12a2 CRISPR enzyme discovered that instead of behaving as a precise gene-editor like Cas9, it goes into an indiscriminate DNA-shredding mode after recognizing its target RNA. By programming it to recognize RNA sequences uniquely activated in cancer cells (embryonic-development genes that shouldn't be running in adults), researchers destroyed only the cancer cells in tissue culture, potentially offering a way to eliminate small metastases without healthy tissue toxicity. Cancer patients who received a COVID-19 mRNA vaccine within 100 days of starting immune checkpoint inhibitor therapy showed dramatically improved outcomes, with median survival in advanced lung cancer rising from 20 to 37 months. Non-mRNA vaccines (flu, pneumonia) showed no such benefit. Lab work suggests the mRNA triggers type-1 interferon release that activates tumor-infiltrating immune cells and drives them to lymph nodes to train other immune cells against the tumor. Researchers redesigned a CD40 agonist antibody to bind multiple receptors simultaneously by clustering with a second antibody, stretching the cell surface and triggering a powerful immune response. In a 12-patient trial, injecting one tumor caused all tumors to shrink in six patients and produced complete remission in two—including a melanoma patient with dozens of leg tumors and a metastatic breast cancer patient whose lung and liver tumors resolved after skin injection. Two small trials of CAR natural killer cells—engineered like CAR T-cells but derived from donor umbilical cord blood and thus potentially available off-the-shelf—showed remarkable results in autoimmune disease. All 27 systemic lupus patients targeting the CD19 protein on autoantibody-producing cells showed improvement, with some remaining in remission at nearly two years. A single Shanghai patient with systemic sclerosis showed restoration of normal skin and blood vessel structure. A paradox has emerged in advanced prostate cancer: while blocking testosterone halts early tumor growth, cancer cells eventually adapt to low-androgen conditions such that flooding tissues with testosterone in advanced disease can actually halt tumor progression by triggering cellular redifferentiation. Separately, Dr. Dawn reviews conflicting evidence on Parkinson's risk from androgen deprivation therapy, singling out enzalutamide (Xtandi) as the most concerning drug due to blood-brain barrier penetration, and recommending darolutamide as the safest alternative with matching prostate efficacy but minimal CNS entry.

Transplant iPSC-derived neurons into a Parkinson's brain and 97% die before they can restore function. Of the 3% that survive, most face the same pathogenic environment that killed the original neurons. This is the compounded biology and CMC problem defining CNS cell therapy today.Bilal Fares, neuroscience entrepreneur and co-founder of AzureCell, is translating a University of Geneva discovery into a genetically engineered iPSC platform built to solve it: neurons that don't just replace what Parkinson's destroyed, but survive the fire that destroyed them.Topics discussed:Why Bilal believes cell therapy is the future of medicine for brain diseases, and the limitations of other approaches (03:06)Bilal's personal story and the events that guided his commitment to Parkinson's research and entrepreneurship (04:03)How cell therapy might move beyond simply replacing lost neurons—using engineered cells to produce therapeutics directly in the brain (09:05)The neuroprotective technology AzureCell is developing, designed to shield transplanted neurons from Parkinson's disease mechanisms (11:31)The platform approach: combining stem cell technologies, genetic engineering, and allogeneic off-the-shelf cell banks (12:38)Why the blood-brain barrier makes cell therapy a necessary approach for certain conditions (13:26)The current status of Azure's preclinical and manufacturing development, and their plans for clinical translation (14:31)Why previous therapies for Parkinson's have fallen short, and how cell therapy might sidestep these limitations (15:57)The potential and challenges of using cell therapy for other brain diseases like Alzheimer's (18:26)Smart insight: The next generation of CNS cell therapy isn't only about neuron replacement. Bilal's thesis reframes transplanted cells as engineered biological factories inside the brain: producing neuroprotective proteins, modulating disease mechanisms in real time, and eventually enabling preventative treatment as manufacturing costs fall and safety matures.If you enjoyed this, check out these episodes on cell therapy, where engineered cells can survive and do more than replace what's lost: Michael Rome's investor lens rounds it out for founders facing the same funding realities.Episodes 269 - 270: How to Turn Mesenchymal Stem Cells into Programmable Cancer Delivery Vehicles with Jun Yung WooEpisodes 253 - 254: How to Source, Manufacture, and Scale the Earliest Stem Cells for Allogeneic Cell Therapy Without Ethical Barriers with Yuta LeeEpisodes 249 - 250: How T Cell Activation Redefines TIL and CAR-T Manufacturing (Boosting Success Rates to 95%) with Chantale BernatchezEpisodes 259 - 260: Why Strong Science Isn't Enough to Get Funded: What Investors Actually Look For with Michael RomeConnect with Bilal Fares:LinkedIn: www.linkedin.com/in/b-fares AzureCell website: www.azurecell.co Email: info@azurecell.coSupport the show

Patients with ROS1-positive NSCLC have a new treatment option following the FDA approval of zidesamtinib for those previously treated with a ROS1 tyrosine kinase inhibitor. In this episode, Dr. Stephen Liu, Dr. Alexander Drilon, and Dr. Rosario Charo Garcia Campelo discuss the ARROS1 trial results, the drug's efficacy and safety profile, CNS activity, and where zidesamtinib may fit into current and future treatment strategies for ROS1-positive lung cancer. Guests: Alexander Drilon, MD Chief, Early Drug Development Service Attending Physician, Thoracic Oncology Service Memorial Sloan Kettering Cancer Center Professor, Weill Cornell Medical College Rosario Charo Garcia Campelo, MD Head of Medical Oncology and Thoracic Tumor Unit, Chair, University Hospital Head of the Oncology Research Group, Biomedical Research Institute A Coruna Spain

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a wealth of significant advancements and strategic moves shaping the industry landscape. AstraZeneca is making waves with its steadfast commitment to reaching an $80 billion revenue target by 2030. This ambitious goal is underpinned by strong sales in oncology and rare disease treatments, despite some setbacks with underperforming drugs like Ultomiris. The company's confidence is further reflected in its robust internal pipeline of antibody-drug conjugates (ADCs), even after discontinuing two candidates that fell short in clinical trials. This move highlights an industry-wide focus on high-potential therapeutic areas, underscoring the critical role of sustained innovation in preserving market leadership. In leadership news, Sarepta Therapeutics has appointed Michael Severino as CEO, succeeding Doug Ingram. Severino's extensive experience from AbbVie and Tessera signals a strategic shift for Sarepta, especially as it hones its focus on therapies for Duchenne Muscular Dystrophy. Leadership transitions like this can significantly impact a company's strategic direction, potentially steering it toward new therapeutic breakthroughs. On the regulatory front, Otsuka's Simtriyo has received FDA approval, marking it as a first-in-class norepinephrine, dopamine, serotonin reuptake inhibitor (NDSRI) for ADHD. This approval is a major leap forward in central nervous system therapeutics, offering a non-stimulant option that could become a blockbuster drug in this underserved market. Such advancements highlight the persistent need for innovative treatments in CNS disorders. Similarly, Outlook Therapeutics has achieved FDA approval for Lytenava, a reformulated version of Roche's Avastin for wet age-related macular degeneration (AMD). This victory, following three prior rejections, exemplifies the challenges and opportunities inherent in drug reformulation and regulatory perseverance. Corporate acquisitions continue to shape industry dynamics. Argenx's acquisition of Forte Biosciences for $2.2 billion exemplifies strategic investments aimed at expanding therapeutic portfolios. Forte's promising Phase 2-stage vitiligo drug acquisition underscores the industry's shift towards biologics in managing complex autoimmune disorders. Amgen's recent layoff of approximately 40 employees aligns with broader trends of operational optimization amidst organizational restructuring. Such workforce adjustments often reflect shifts in business strategy or responses to evolving market conditions. In clinical development news, InnoCare Pharma has announced successful Phase 3 results for its oral TYK2 inhibitor Fadeucravacitinib in treating moderate-to-severe plaque psoriasis. This achievement underscores the potential of targeted therapies in addressing autoimmune conditions by modulating specific signaling pathways. The FDA's approval of Freenome's SimpleScreen CRC blood test marks a significant advancement in non-invasive diagnostic tools for colorectal cancer screening. Such innovations could dramatically impact early cancer detection and improve patient outcomes. Meanwhile, emerging insights into CAR-T therapy have identified genetic markers linked to toxicity risks in Yescarta patients. These findings can guide future CAR-T product development towards enhanced safety profiles, offering pathways for engineering safer therapies by identifying patients at higher risk for adverse effects. Finally, the partnership between Salesforce and Veterans Affairs aims to integrate AI into healthcare workflows, illustrating the increasing role of digital transformation in enhancing healthcare delivery and operational efficiency. These developments highlight the ongoing evolution towards more personalized and efficient healthcare solutions within the pharmaceutical and biotech sectors. As companies navigate complex regulatory landscapes, pursue innovative therapies, and adapt to dynamic market demands, their efforts are poised to advance patient care standards and drive future growth within these critical industries. The implications for patient care are profound, as new treatments offer hope for conditions that have long eluded effective intervention. Stay tuned with Pharma Daily as we continue to bring you the latest updates from this rapidly evolving field.Support the show

In collaboration with ROESCG, we introduce a new series, Cancer Careers! Today we're joined by Dr. Justin Oh, a Radiation Oncologist at BC Cancer in Vancouver who specializes in CNS and pediatric cancers, and has a strong research interest in population-based outcomes.

BloodCancerTalks: ASCO/EHA 2026 Lymphoma Round-Up with Dr. Thomas LewGuest: Dr. Thomas Lew, Peter MacCallum Cancer Centre (Melbourne, Australia) — hematologist specializing in lymphoid malignancies.In this episode, we break down the biggest lymphoma and CLL data from ASCO and EHA 2026 (Chicago and Stockholm), covering mantle cell lymphoma genomics, bispecific antibodies in DLBCL and follicular lymphoma, a practice-changing (or not) CNS prophylaxis study, transplant-eligible relapsed DLBCL, fixed-duration BTK/BCL2 combinations in CLL, and the first in vivo CAR T data in lymphoma.1. TRIANGLE: TP53-Mutated MCL Molecular Subgroup AnalysisMolecular subgroup data from the practice-shaping TRIANGLE trial presented by Dr. Marta Grau.Discussion: Where TP53-mutated MCL stands today, and whether ibrutinib-containing regimens are changing the natural history of this historically dismal subgroup.2. EPCORE DLBCL-1: Epcoritamab vs. Chemotherapy in R/R DLBCLRandomized phase 3 trial (n=483) of bispecific antibody epcoritamab vs. investigator's choice chemotherapy (72% R-GemOx, 28% BR) in second-line-or-later, transplant-ineligible R/R DLBCL, presented by Prof. Chris Fox.Discussion: A PFS benefit without an OS signal, set against a meaningfully higher infection-related mortality — what this means for patient selection and infection mitigation strategies.3. CNS Prophylaxis in Ultra-High-Risk DLBCL: Does HD-MTX Help?Pooled analysis of two large multicenter retrospective cohorts (n=1,923 ultra-high-risk patients — CNS-IPI 5–6, testicular/renal/adrenal/breast involvement, or ≥3 extranodal sites), presented by Dr. Matt Wilson (Glasgow) and simultaneously published in JCO. Discussion: Whether these data close the door on routine HD-MTX in ultra-high-risk DLBCL, and if any subgroup still warrants prophylaxis.4. Pola-R-ICE: A Negative Trial in Transplant-Eligible R/R DLBCLRandomized phase 3 study (4 European cooperative groups; n=294) of polatuzumab vedotin added to R-ICE in transplant-eligible R/R DLBCL, with ASCT/alloSCT/CAR-T permitted as consolidation.Discussion: Why this trial missed, and what it tells us about the ceiling of intensive salvage chemo-immunotherapy platforms in the CAR-T era.5. BRUIN-CLL-322: Fixed-Duration Pirtobrutinib + Venetoclax-Rituximab in R/R CLLRandomized phase 3 trial (n=639) of fixed-duration pirtobrutinib (non-covalent BTKi) plus venetoclax-rituximab (PVR) vs. venetoclax-rituximab (VR, the MURANO-based control) in second-line-or-later R/R CLL.6. SOUNDTRACK-F1: Surovatamig (CD19 Bispecific) Safety Run-In in Untreated Follicular LymphomaSafety run-in from a randomized trial (surovatamig vs. chemoimmunotherapy) in untreated FL meeting GELF criteria, presented by Prof. Chan Cheah — building on EPCORE-FL-1 data presented at ASH.Discussion: How this CD19-directed bispecific compares to CD20-targeting agents in frontline FL.7. LB2501: First In Vivo CAR T Data in B-Cell LymphomaLate-breaking data from Dr. Lei Fan and Legend Biotech on LB2501, an in vivo CD19/CD20 dual-targeted CAR T therapy — a third-generation, self-inactivating, replication-incompetent lentiviral vector that generates CAR T cells directly in vivo, without lymphodepletion. Builds on the in vivo CAR T myeloma data first presented at ASH and updated at EHA.Discussion: What these very early but striking data suggest about the feasibility of in vivo CAR T generation in lymphoma, and how it might reshape access to cellular therapy.BloodCancerTalks is co-hosted by Rajshekhar Chakraborty,  Ashwin Kishtagari and Eddie Cliff. Subscribe wherever you get your podcasts. 

Two Onc Docs, hosted by Samantha A. Armstrong, MD, and Karine Tawagi, MD, is a podcast dedicated to providing current and future oncologists and hematologists with the knowledge they need to ace their boards and deliver quality patient care. Dr Armstrong is a hematologist/oncologist and assistant professor of clinical medicine at Indiana University Health in Indianapolis. Dr Tawagi is a hematologist/oncologist and assistant professor of clinical medicine at the University of Illinois in Chicago.In this episode, OncLive On Air® partnered with Two Onc Docs to deliver a comprehensive, board-focused review of diffuse large B-cell lymphoma (DLBCL) for 2026, updating their prior coverage to reflect several recent practice changes.The discussion began with clinical presentation, emphasizing the classic B symptoms—weight loss, night sweats, fatigue, and fever—alongside painless, rapidly enlarging lymphadenopathy. They noted that approximately 30% to 40% of cases present with extranodal involvement (gastrointestinal, central nervous system [CNS], or thyroid) and stressed that an excisional biopsy is required, as fine-needle aspiration cannot preserve the architecture needed for histologic grading.Turning to classification, Drs Armstrong and Tawagi reviewed germinal center vs non-germinal center origin, with non-germinal center disease carrying a worse prognosis. They characterized double-hit lymphoma, triple-hit lymphoma, and double-expressor lymphoma, the last conferring an intermediate prognosis.Regarding workup, they recommended full-body PET scans, laboratory evaluation for tumor lysis syndrome, hepatitis B testing before anti-CD20 therapy, baseline echocardiography before anthracyclines, and lumbar puncture with intrathecal methotrexate in patients at high risk for CNS relapse. They also reviewed updated staging systems.For treatment, they explained that limited-stage disease is now stratified by the stage-modified International Prognostic Index (IPI), guiding abbreviated vs full R-CHOP (rituximab [Rituxan], cyclophosphamide, doxorubicin, vincristine, and prednisone). In advanced disease, 6 cycles of R-CHOP remains standard, with polatuzumab vedotin-piiq (Polivy) plus R-CHP (rituximab, cyclophosphamide, doxorubicin, and prednisolone) now a category 1 regimen for patients with an IPI of 2 or greater. They also addressed dose-adjusted regimens for double-hit disease, CAR T-cell therapy, and bispecific antibodies in the relapsed/refractory setting, as well as surveillance recommendations, cautioning against routine PET imaging.

In this episode the guys break down six ways to build bulletproof joints — proper strength training, unilateral training, static stretching post-workout, mobility drills, hydration with high protein diet, and consistent sleep. They cover why joints actually strengthen rather than wear down with proper use, why MAPS Symmetry alone solves most chronic pain issues without targeted correctional exercise, and why CNS tightening after workouts causes the low back pain people feel hours later at night. They also get into a new study showing probiotics plus protein powder outperforms protein powder alone for strength gains, creatine reducing anxiety in 95% of postmenopausal women, Sal's return to jiu jitsu and the cardio humbling he's getting from a one-year practitioner, Doug's 4th of July river rafting trip on the American River, Sal's son's emotional breakdown watching the USA World Cup loss, and Adam going deep on the Vuori wetsuit situation. Then they answer questions from Instagram. MAPS Upper Lower: https://mapsupperlower.com Code: LAUNCH for 40% off. Male and female programs, workout videos, exercise demos and live coaching with Cole. SPONSORS LMNT (electrolytes): https://drinklmnt.com/MindPump Free 8-count sample pack with any purchase. No code needed. No-questions-asked refunds on all orders. Discussed on air — Sal swears by it before sauna and the study on electrolytes and migraines. Vuori: https://vuoriclothing.com/mindpump 20% off first order, no code needed, automatically applied. Doug wore their wetsuit for the first time on the rafting trip. Caldera Lab (Hydro Layer skincare): https://calderalab.com/mindpump Code: MINDPUMP20 for 20% off first order. Visibly reduces lines and wrinkles, firms skin, all-day hydration. 90%+ of users report visible improvement quickly. LINKS Mind Pump Store: https://mindpumpstore.com Maps Fitness Products: https://mapsfitnessproducts.com Instagram: @mindpumpmedia SPOTIFY TIMESTAMPS 0:00 - Intro 0:13 - How to build bulletproof joints — can joints actually get stronger? 3:20 - Tip #1: Proper strength training — data shows cartilage gets thicker with proper training 9:12 - Tip #2: Unilateral training — why MAPS Symmetry alone corrects most chronic pain 13:08 - Why the weaker side has to dictate the workout and why this is psychologically hard 18:28 - Tip #3: Static stretching post-workout — why your CNS stays tight after training and causes late-night pain 23:01 - Tip #4: Mobility drills — owning ranges of motion through active movement 26:26 - Tip #5: Hydration and high protein — lubrication, connective tissue and why collagen hype has merit 22:00 - Tip #6: Sleep — the number one recovery and adaptation tool 23:01 - LMNT deep dive — the downstream benefits, electrolytes and migraines study 27:06 - Endurance study: 120g carbs per hour means cyclists lose less than a third of their power 28:20 - Sal's jiu jitsu update — getting humbled by a one-year practitioner on cardio efficiency 34:14 - Doug's 4th of July American River rafting trip — wetsuit success and guide goes overboard 43:00 - Sal's son breaks down crying watching USA lose the World Cup 51:07 - Probiotics plus protein beats protein alone for strength gains 52:12 - Creatine reduces anxiety in 95% of postmenopausal women 58:22 - Q&A: One muscle group once per week vs. twice per week for natural lifters 1:00:27 - Q&A: How can you lose muscle and gain fat while in a calorie deficit? 1:00:27 - Q&A: Best home exercises to improve ankle mobility 1:01:39 - Q&A: What other neglected muscles and exercises should people be training?

Featuring a slide presentation and related discussion from Prof Dr Sibylle Loibl, including the following topics: ·      Overview of the changing landscape of treatment for patients with HER2-positive metastatic breast cancer (mBC) (0:00) ·      Results from the CLEOPATRA, PATINA and HER2CLIMB-05 trials of first-line treatment and maintenance approaches for HER2-positive mBC (5:26) ·      Efficacy and safety findings from the Phase III DESTINY-Breast09 trial comparing trastuzumab deruxtecan with or without pertuzumab to taxane/trastuzumab/pertuzumab as first-line therapy for HER2-positive mBC (14:56) ·      Predictors of long-term benefit from first-line treatment with HER2-targeted agents; contribution of pertuzumab to the efficacy of first-line HER2-targeted combination regimens (22:57) ·      Control of brain metastases and CNS disease with first-line HER2-targeted regimens (26:31) CME information and select publications

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into the latest news and insights that are shaping the landscape of patient care and drug development. The U.S. FDA has expanded the label for Pfizer and Astellas' Padcev, in combination with Merck's Keytruda, to include all muscle-invasive bladder cancer patients. This significant regulatory update broadens access to a combination therapy that merges an antibody-drug conjugate with a PD-1 inhibitor, offering enhanced treatment options for patients unable to tolerate cisplatin, a common chemotherapy drug. The decision marks a pivotal step forward in providing more inclusive and effective treatment regimens for bladder cancer. In Scotland, Roche's Columvi has been endorsed by the Scottish Medicines Consortium for use in treating relapsed or refractory diffuse large B-cell lymphoma. This approval highlights the growing importance of bispecific antibodies in oncology, which can simultaneously engage two different antigens to enhance anti-tumor responses. Such innovations underscore the ongoing transformation of cancer treatment through combination therapies. Across the Atlantic, Health Canada has approved Clinuvel's Scenesse for erythropoietic protoporphyria (EPP), a rare condition causing extreme light sensitivity. Scenesse acts as a melanocortin receptor agonist, offering photoprotection and improving quality of life for those affected by this debilitating disorder. On the business front, Bayer's strategic partnership with Apollo has secured a €3 billion equity deal for its long-acting reversible contraceptives business. This move underscores a growing emphasis on women's health and contraceptive innovation. Likewise, CMS and Insilico's collaboration aims to harness artificial intelligence for CNS drug discovery, promising to accelerate drug development through AI-driven target identification. Clinical trials continue to reveal promising developments. Eisai's Etalanetug is showing potential in reducing tau tangle biomarkers in dominantly inherited Alzheimer's disease. Similarly, Eisai and BioArctic's Leqembi subcutaneous autoinjector demonstrates comparable efficacy to its intravenous counterpart, potentially improving compliance and accessibility for early Alzheimer's patients through less invasive administration methods. Financially, Apnimed is planning an IPO to support its sleep apnea pill's commercial launch, while Velogene Biotechnology has secured Series A funding to advance its gene-editing platform. These financial activities highlight ongoing investments in innovative solutions aimed at addressing unmet clinical needs. Yet, challenges persist as well. The FDA has rejected Hengrui and Elevar Therapeutics' combination treatment for hepatocellular carcinoma for a third time, emphasizing the difficulties of meeting regulatory standards and demonstrating efficacy. Additionally, Germany's new healthcare cost-saving law has doubled pharmaceutical rebate rates, sparking industry concern over potential impacts on profitability and innovation investment. The regulatory landscape continues to evolve with the FDA proposing streamlined registration processes under the "hub-and-spoke" model to enhance transparency and security within supply chains. Meanwhile, recent FDA transparency actions have led to the release of 14 drug rejection letters, underscoring ongoing challenges in securing approvals due to stringent regulatory requirements. Geographically, emerging biotech hubs like Basel and Beijing are gaining prominence as global talent hotspots due to their conducive environments for research and development collaboration. These regions are becoming increasingly attractive for biopharmaceutical innovation. Amid fierce competition in obesity management solutions, Lilly's launch of its oral GLP-1 receptor agonist Foundayo faces stiff competition from Novo Nordisk's Wegovy pill. The race reflects broader trends toward developing patient-centric therapies that offer convenience alongside therapeutic efficacy. Intellectual property strategies are also evolving as companies employ new patent tactics to maintain competitive advantages in crowded markets. Safety remains a top priority as exemplified by Lupin Pharmaceuticals' recall of contaminated eye drops, highlighting ongoing challenges in ensuring product safety. Lastly, advancements in wearable technology offer promising improvements in patient care; however, integration into clinical practice is met with infrastructural hurdles—a sentiment echoed by healthcare professionals surveyed by the AMA. Overall, these developments paint a complex picture of scientific innovation intersecting with regulatory evolution and strategic industry adaptations aimed at enhancing patient outcomes while navigating economic pressures. As the industry evolves, stakeholders must remain vigilant and adaptable to seize opportunities and address challenges effectively.Support the show

Julie Wendt, MS, LDN, CNS, adjunct instructor, Integrative Medicine Programs, Department of Clinical Research and Leadership, GW School of Medicine & Health Sciences, recently gave a talk on staying hydrated as the temps and humidity rise to summertime highs. As Licensed Dietician Nutritionist (LDN), Julie is a highly trained food and nutrition expert. LDNs and Registered Dietitian Nutritionists (RDN) are the only credentialed professionals legally qualified to provide medical nutrition therapy, assess nutritional needs, and build specialized meal plans for specific medical conditions. She is a LDN is Maryland, a Licensed Nutritionist in D.C., and a Certified Nutrition Specialist (CNS). Julie earned a Masters of Science in Integrative Health and Nutrition from Maryland University of Integrative Health. ◘ Related Links Julie Wendt Nutrition www.juliewendtnutrition.com Julie's Hydration Checklist https://bit.ly/4w0xx00 ◘ Transcript bit.ly/3JoA2mz ◘ Disclaimer: The content and information shared in GW Integrative Medicine is for educational purposes only and should not be taken as medical advice. The views and opinions expressed in GW Integrative Medicine represent the opinions of the host(s) and their guest(s). For medical advice, diagnosis, and/or treatment, please consult a medical professional.

We love to hear from our listeners. Send us a message. This week's episode of the Business of Biotech was recorded at the BIO Convention in San Diego, where guest Maha Radhakrishnan, M.D., Executive Partner, Private Equity, at Sofinnova, spoke about her move from big pharma and biotech to private equity investing, and what makes a late-stage asset deal work. Maha also talks about how China-originated programs are changing development timelines, and where the next wave of CNS and metabolic innovation could come from. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.  Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

It was an absolute honor to meet today's guest, and I was honestly a bit starstruck! She is rooted equally in both the science of food and intuitive eating. We dove into the phytochemistry of nutrients, and most importantly, discussed the fundamental principles for healthy eating. Dr. Deanna Minich, PhD, CNS, IFMCP is a pioneering nutrition scientist and thought leader with over 25 years of experience bridging science, spirituality, and art to redefine holistic health. Internationally recognized for her work on color-coded nutrition (“eating the rainbow”), detoxification, and hormone health, Dr. Minich brings a multidimensional lens to wellness that is both grounded in research and infused with a soulful approach. For over a decade, she worked closely with the “Father of Functional Medicine,” Dr. Jeffrey Bland on R&D and functional medicine education with the Institute for Functional Medicine and assisting with the start-up of the Personalized Lifestyle Medicine Institute (PLMI) and now on the Board for PLMI. In 2025, she was awarded the Linus & Ava Helen Pauling Award by the Institute for Functional Medicine, one of the highest honors in the field, for her groundbreaking contributions to science-backed integrative health. As the Chief Science Officer at Symphony Natural Health, Dr. Minich leads the Science-Medical Team's innovation in endocrine, metabolic, and circadian health, developing evidence-based approaches that empower people to reclaim vitality through rhythm, root-cause healing, and renewal. A passionate educator and communicator, she develops transformative curricula and continuing education for health professionals, while also creating accessible, inspiring resources for the general public. Her work meets people where they are, whether they're practitioners seeking clinical precision or individuals seeking a deeper connection to their body's wisdom. Connect with Dr. Deanna via: Email: info@foodandspirit.com Website: Dr. Deanna Minich FB: Deanna Minich, PhD IG: @deannaminich YT: @foodandspirit Linked In: Deanna Minich, PhD, MS, FACN, CNS, IFMCP Visit https://marinabuksov.com for more holistic content. Music from https://www.purple-planet.com. Disclaimer: Statements herein have not been evaluated by the Food and Drug Administration. Products listed are not intended to diagnose, treat, cure, or prevent any diseases.

Broadcast from KSQD, Santa Cruz on 6-25-2026: Dr. Dawn devotes the show's opening to ivermectin for COVID. She walks through critical thinking principles—considering the source, cross-verification, and recognizing self-interested claims—before reviewing the evidence. The most-cited 2021 Bulgarian study of 300 people showing 77% reduction lacked accessible methods, and larger trials capable of detecting even small benefits failed to confirm efficacy. On safety, the standard 12mg parasitic dose every few weeks is well-tolerated due to the blood-brain barrier and efflux pumps that keep ivermectin out of the brain, but daily long-term dosing has caused encephalopathy, liver and kidney damage, and birth defects. Critical drug interactions—macrolide antibiotics, verapamil, proton pump inhibitors, and beta blockers—disable the efflux mechanism, and high-fat meals increase absorption 2.5-fold. Dr. Dawn shares two inflammation formulas calculable from any CBC. The Systemic Inflammatory Index (neutrophils × platelets ÷ lymphocytes) flags runaway inflammation: 200-500 is good, above 900 warrants investigation and correlates with worse stroke outcomes and rising tumor burden. The SIRI (neutrophils x monocytes ÷ lymphocytes) detects chronic tissue inflammation and early innate immune activation: below 500 is good, above 1500 indicates trouble and correlates with cardiovascular mortality and arterial plaque from M1 macrophage activity. Dr. Dawn shares two takeaways from the Institute for Functional Medicine annual conference: in patients at high cardiovascular risk by cholesterol, each gram daily of combined EPA/DHA produces a 9% risk reduction, with bruising as the dose-limit signal. Additionally, a 15-minute walk within 30 minutes of a meal nearly eliminates postprandial inflammation. An emailer asks whether an endocrinologist's claim that vitamin D leaches calcium from bones is true. Dr. Dawn confirms that very high vitamin D (above 150 nanograms, with concern starting above 90) elevates 1,25-vitamin D, which stimulates osteoclast formation and increases C-telopeptide markers of bone breakdown. A crowdsourced question asks how histamines work in women. Dr. Dawn explains histamine functions as a CNS neurotransmitter promoting alertness, wakefulness, and pain perception (deficient in narcolepsy), and as a GI signal driving acid secretion, motility, and visceral sensation. Gut bacteria can convert histidine to histamine, and fish left to spoil can trigger anaphylactic-like reactions from accumulated bacterial histamine. She notes stomach acid treatments Tagamet and Zantac are H2 blockers rather than the more familiar H1 antihistamines, and confirms histamine correlates with hormones but not particularly with minerals. A crowdsourced question on B vitamins for women in their mid-twenties prompts Dr. Dawn to recommend prenatal vitamins for those who might become pregnant, and B100 complex with calcium taken with a little apple cider vinegar for those on restricted diets or eating mostly fast food. Another question asks about chest versus belly breathing. Dr. Dawn explains babies demonstrate proper diaphragmatic breathing (belly protrudes on inhalation) while accessory muscle use signals fight-or-flight—or pneumonia in a non-crying infant. Chest breathing raises adrenaline; belly breathing calms it in adults. How do I stop compulsive scratching? Dr. Dawn explains neurodermatitis has its own ICD-10 code alongside compulsive nail-biting and hair-pulling, and it is diagnosed by sparing of unreachable areas like the mid-back between shoulder blades. Treatment includes nail clipping, lubricants, covering scabbed areas, and Prozac—which uniquely among antidepressants has a secondary indication for neurodermatitis. Zurich researchers combined immature human nerve cells with magnetic nanoparticles to create 6-micrometer NPC bots that can be magnetically positioned at spinal cord injury sites and then triggered by pulsatile magnetic stimulation to mature into nerve tissue. Mice with severed spinal cords regained movement and brain-muscle electrical signals by day 34 after daily 30-minute treatments. A study of 15,000 people with myalgic encephalomyelitis/chronic fatigue syndrome identified eight genetic regions distinguishing them from controls. Two relate to immune response to infection—consistent with the post-infectious onset many sufferers describe, including roughly half of long COVID patients—and others link to the nervous system and chronic pain. Dr. Dawn frames ME-CFS as an immune system stuck in the "on" position, unable to brake against an enemy that is long gone. An emailer asks about prostate biopsy approaches. Dr. Dawn explains the new transperineal biopsy (through skin between scrotum and anus) reduces post-biopsy infection from 1.5% to near zero and eliminates prophylactic antibiotics, though it requires more anesthesia and time. Cancer detection rates match the transrectal approach when both use MRI targeting, and she expects the transperineal approach to become standard.

Send us Fan MailStarting January 1, 2027 every antepartum visit becomes its own billable E/M charge. The global OB code goes away. The seventeen deleted codes include 59400, 59510, 59425, and 59426. And the way most prenatal notes are written today supports a 99212 at best, even when the visit was genuinely a 99214. Dr. Heather Signorelli and Maria Reynoso, Director of RCM at NatRevMD, walk through what changes, what the notes have to say, and the three actions every OB practice should take this week. What changes January 1, 2027: Antepartum-only codes (59425, 59426) and global OB codes (59400, 59510) are deleted. Every prenatal visit is now a standard E/M visit with modifier TH. New patient 99202–99205. Established patient 99211–99215. What the notes actually look like today: Notes have been written for speed because the global model did not reward note detail. A typical 16-week prenatal note (BP, fundal height, FHTs, “patient doing well, return in 4 weeks”) supports a 99212. The provider did much more during that visit. None of it is in the note. Under 2027, that gap is real revenue. What a 99214 note has to say: ACOG's position: pregnancy is a chronic illness with exacerbation and progression for E/M purposes. The complexity is built in. The note has to reflect it. For a 99214, document the ongoing management of the pregnancy as a condition, the data reviewed with your interpretation, and moderate risk decisions like prescription management or monitoring a condition that could escalate. “Anatomy scan reviewed, normal” is a 99212. “Anatomy scan reviewed, normal four-chamber heart, no CNS abnormality, EFW consistent with dates, AFI normal, counseled patient” is a 99214. High-risk patients finally pay for the complexity of their care: Under the global model the complex patient and the low-risk patient paid the same. The new model fixes that two ways. Complex visits code at a higher level (99214 / 99215). And more frequent visits equal more claims. For 99215 the note needs the specific complicating diagnosis named, data reviewed with interpretation, the management decision and the reason behind it, and specialist coordination if applicable. Same-day procedures and modifier 25: Antepartum procedures (NSTs, ultrasounds, amniocentesis, CVS) still bill separately. The E/M visit on the same day is now also billable with modifier 25. The note must independently support the E/M, not just the procedure. Three actions this week: Audit twenty random prenatal notes against the 2021 E/M guidelines to set your baseline Rebuild EHR templates to prompt for MDM elements, not for speed Start documentation training in Q3, using providers' own notes side by side with the corrected version and the dollar difference Quick Reference Table:       Topic                                                                                    What to knowDeleted codes count                     -      17 codes deleted total Antepartum-only codes                  -       59425, 59426 — deleted Jan 1, 2027Global OB codes                                  -       59400, 59510 — deleted Jan 1, 2027 New patient E/M range                    -       99202–99205 + modifier TH Established patient E/M range    -       99211–99215 + modifier TH 99214 vs 99213                              -       ~$46 per visit at Medicare ratesModifier 25               -       On the E/M when a procedure is also billed same dayACOG test date         -September 1, 2026 — recommended start for test claimsRVU finalization       - CMS proposes July 2026, finalizes November 2026 RESOURCES BLOCK Save your seat: Live OB/GYN Global Codes Update Webinar (July 7, 2026, 4:00 PM ET) · eligibility.natrevmd.com/obgyn-global-updates-webinar Book a 1:1 with Dr. Signorelli · calendly.com/heather-natrevmd/ Practice Revenue Leak Scorecard · eligibility.natrevmd.com/nrm-revenue-scorecard-v3 Payment Posting Audit Checklist · eligibility.natrevmd.com/payment-posting-checklist RECOVER Diagnostic Quiz · natrevmd.com/quiz Series Part 1 (EP188): https://podcasts.apple.com/us/podcast/188-17-ob-codes-just-got-deleted-your-real-deadline/id1624182351?i=1000773393336Coming next: EP191 · Phase 2 labor management codes (the codes that have never existed in CPT before) 

Could Hashimoto's be the missing root cause behind your thyroid symptoms?If you have been told your thyroid labs are “fine,” or you are taking thyroid medication but still feel exhausted, foggy, inflamed, or not like yourself, this conversation will help you understand what may be happening underneath the surface. Hashimoto's is not just a thyroid problem. It is an immune system condition that can keep attacking the thyroid when the deeper triggers are never addressed.Inna Topiler, CNS, MS, is a Certified Nutrition Specialist who has navigated her own Hashimoto's journey for over 25 years. She is the host of Thyroid Mystery Solved: Hashimoto's and Hypothyroidism Revealed, and the creator of Thyroid Love, a 26-nutrient supplement formulated specifically for thyroid autoimmunity.In this conversation with Dr. Shivani Gupta, Inna explains the immune confusion behind Hashimoto's, why thyroid medication alone does not calm the immune attack, and what it really takes to support thyroid health at the root.What You'll Learn in This Episode:Why levothyroxine supports the thyroid but does not address the immune attack causing the damage?How to ask for a real full thyroid panel, and why TPO and TG antibodies matterThe four root cause buckets behind immune confusion: food, infections, toxins, and stressWhy gluten can trigger an immune attack on the thyroid through molecular mimicryThe truth about iodine supplementation with Hashimoto's, and why it often makes things worseHow selenium and inositol support thyroid hormone balance and immune regulationWhy zinc deficiency can be generational and how high copper compounds the problemWhat a thyroid supplement designed for autoimmunity should and should not includeThe Inflammation Codehttps://www.amazon.com/dp/140199699X?tag=usalinktagdefault-20&th=1&psc=1&geniuslink=trueFusionary Formulas SupplementsUse code CODE15 for 15% off your first orderhttps://fusionaryformulas.com/?utm_source=Show+Notes&utm_medium=Show+notes+&utm_campaign=Podcast+promo&utm_id=The+Inflammation+Code+Podcast7-Day Inflammation Detox Challengehttps://www.7dayinflammationdetox.com/Work with Dr. Shivani / Free Discovery Callhttps://shivanigupta.com/

Many disease‑causing genes are too large to be packaged into standard AAV gene therapy vectors, leaving a long list of otherwise gene-therapy-ready conditions without viable treatments. SpliceBio is leveraging a protein splicing platform based on engineered split inteins to overcome the cargo limitations of AAV gene therapy vectors, enabling delivery of large genes to potentially treat a broad range of monogenic conditions. The company's lead program is a dual AAV gene replacement therapy to treat Stargardt disease, a rare inherited condition that causes progressive vision loss. Miquel Vila-Perello, CEO of SpliceBio, discusses the company's platform technology that enable to the delivery of large genes in AAV vectors, its work to date in Stargardt disease, and preclinical data across more than 20 large-gene targets supporting its platforms use in ophthalmology and CNS indications.

I sit down with nutrition scientist Dr. Luke Bucci to explore the powerful connection between blood flow, nitric oxide, mitochondrial health, and healthy aging. We discuss why circulation impacts nearly every function in the body, what causes energy levels to decline with age, and how nutrition, exercise, and targeted supplementation may help support long-term vitality. Dr. Bucci also explains the science behind nitric oxide, blood sugar regulation, and the role mitochondria play in keeping us energized and resilient throughout life.Dr. Luke Bucci, PhD, CNS, CCN is the Chief Scientific Officer of Juvenon and a biomedical scientist with more than 40 years of experience in nutrition, dietary supplements, and clinical laboratory science. He earned his PhD in Biomedical Sciences from the University of Texas Health Science Center at Houston and has helped develop numerous patented nutritional products used worldwide. A recognized authority in healthy aging, sports nutrition, omega-3s, probiotics, and dietary supplement science, Dr. Bucci has authored scientific books, taught university-level courses, and received multiple industry awards for his contributions to nutrition and health innovation.Links mentioned during this episode:Juvenon: https://juvenon.com/Free Initial Consultation with Dr. Megan: https://p.bttr.to/3a9lfYkLyons' Share Instagram: www.instagram.com/thelyonsshareJoin Megan's newsletter: www.thelyonsshare.org/newsletter

Life sciences is a hub of dealmaking activity. Over the past year, more than 30 transactions valued at $1 billion or more have crossed the finish line. But the picture in other segments of healthcare is more mixed. At RBC Capital Markets' Global Healthcare Conference in New York, Darren Campili, Global Head of Healthcare Investment Banking, hosts colleagues David Levin, Ahmed Attia and Jason Levitz to explore what's driving deals and where the opportunities are heading.Key PointsHealthcare M&A is strong, with a surge of high-value deals in life sciences.Equity performance is challenging, but investors in life sciences and biotech have seen good outcomes.IPO activity has rebounded; again, life sciences and biotech are most successful.Dealmaking has been largely unaffected by regulatory uncertainty, though challenges remain on reimbursement and MFN pricing.Larger companies believe they have the edge in using AI for profitability and competitiveness.Introductions [00:25]Host Darren Campili, Global Head of Healthcare Investment Banking, introduces the podcast and guests: David Levin, Co-Head of U.S. M&A; Ahmed Attia, Managing Director, Healthcare M&A; and Jason Levitz, Head of Healthcare Equity Capital Markets.M&A strength in healthcare [01:11]The M&A market in life sciences is extremely strong. The number of $1 billion-plus deals has tripled in the past year. There has been significant activity among mid-caps as well as large-cap companies, and a diversity of premiums.Healthcare in the equity markets [13:24]In the broader context of the U.S. equity markets, healthcare is performing poorly, particularly among large-cap medtech and services companies. At the same time, life sciences and biotechs are outperforming, leading to diverse outcomes for investors.IPO activity [15:20]IPO volumes have rebounded after some disappointing years. Deal flow has centered on oncology, I&I, and CNS.Political impact [24:15]Dealmaking has continued despite uncertainty over the FDA. Tariff policy has been a net positive for U.S. inflows as pharma businesses seek U.S. capabilities. Managing reimbursement and Most Favored Nation pricing remains challenging for some.

Life sciences is a hub of dealmaking activity. Over the past year, more than 30 transactions valued at $1 billion or more have crossed the finish line. But the picture in other segments of healthcare is more mixed. At RBC Capital Markets' Global Healthcare Conference in New York, Darren Campili, Global Head of Healthcare Investment Banking, hosts colleagues David Levin, Ahmed Attia and Jason Levitz to explore what's driving deals and where the opportunities are heading.Key PointsHealthcare M&A is strong, with a surge of high-value deals in life sciences.Equity performance is challenging, but investors in life sciences and biotech have seen good outcomes.IPO activity has rebounded; again, life sciences and biotech are most successful.Dealmaking has been largely unaffected by regulatory uncertainty, though challenges remain on reimbursement and MFN pricing.Larger companies believe they have the edge in using AI for profitability and competitiveness.Introductions [00:25]Host Darren Campili, Global Head of Healthcare Investment Banking, introduces the podcast and guests: David Levin, Co-Head of U.S. M&A; Ahmed Attia, Managing Director, Healthcare M&A; and Jason Levitz, Head of Healthcare Equity Capital Markets.M&A strength in healthcare [01:11]The M&A market in life sciences is extremely strong. The number of $1 billion-plus deals has tripled in the past year. There has been significant activity among mid-caps as well as large-cap companies, and a diversity of premiums.Healthcare in the equity markets [13:24]In the broader context of the U.S. equity markets, healthcare is performing poorly, particularly among large-cap medtech and services companies. At the same time, life sciences and biotechs are outperforming, leading to diverse outcomes for investors.IPO activity [15:20]IPO volumes have rebounded after some disappointing years. Deal flow has centered on oncology, I&I, and CNS.Political impact [24:15]Dealmaking has continued despite uncertainty over the FDA. Tariff policy has been a net positive for U.S. inflows as pharma businesses seek U.S. capabilities. Managing reimbursement and Most Favored Nation pricing remains challenging for some.

Mini Episode 1 - airs June 9, 2026 The Wholistic Take: Health News and Trends through a Wholistic Lens The Wholistic Take is a podcast series on the Wholistic Matters Podcast. We explore the latest health news and trends from a wholistic health perspective. The Wholistic Take episodes are shorter in length for easier consumption and timely delivery. We track the latest health news and offer wholistic insights for you to use in clinical practice and for personal care. HOST: Dr. Daina Parent, ND GUEST: Betsy Miller, MS, CNS, RH(AHG), DCN-c In this mini episode, Dr. Daina Parent and Betsy Miller discuss the recent renaming of the condition formerly known as PCOS, know renamed PMOS. They cover what this name change means, why it's important and how it will affect women's healthcare going forward. Parent and Miller emphasize the importance of a holistic approach in managing PMOS symptoms, including lab testing, diet, herbs, nutrients, and lifestyle. Betsy Miller, MS, CNS, RH(AHG), DCN-c is a clinical herbalist and certified nutrition specialist with a passion for women's health, evidence-based medicine and patient-centered care. Over the past 15 years she has devoted herself to building a clinical practice, cultivating critical research skills and teaching herbal medicine at the graduate level. She is the Clinical Product Support Manager at Standard Process and contributes digital education content for the Wholistic Matters website. Podcast Summary 1:35 PCOS is now PMOS – why is this news? 2:55 How the new name will help woman receive the proper diagnosis 4:33 LH:FSH Ratio – when and how to test for these 5:24 Supporting symptoms of PMOS including insulin resistance, ovulation, and hyperandrogenism 6:48 Lab testing, nutrients and herbs for blood sugar regulation 9:57 Menstrual Irregularities – individualized approach paired with labs, nutrients and herbs 14:11 Supporting hyperandrogenism and hirtuism 15:19 How to support fertility challenges 17:24 Diet and lifestyle recommendations for managing PMOS

In this episode of the Oncology Brothers podcast, we discussed challenging cases focused on metastatic non-small cell lung cancer (NSCLC) with common EGFR mutations. Joined by experts Dr. Shirish Gadgeel from the Emory University and Dr. Wade Iams from Tennessee Oncology, the discussion revolved around two real-life patient cases. The first case featured a 54-year-old gentleman with active tobacco use and diffusely metastatic NSCLC, including an isolated brain lesion. The panel explored treatment options, including single-agent osimertinib versus dual combinations of amivantamab-lazertinib and osimertinib-chemotherapy, emphasizing the importance of shared decision-making and considering co-mutations and patient demographics. In the second case, the conversation shifted to supportive care and managing side effects, particularly focusing on skin toxicity associated with amivantamab. The experts shared their proactive approaches to patient education and the significance of monitoring and adjusting treatment plans to enhance patient quality of life.   Key Points: In EGFR-mutated NSCLC with CNS metastases, treatment selection between single-agent osimertinib and combination amivantamab-lazertinib vs. osimertinib-chemotherapy requires individualized consideration of age, co-mutations, extent of disease, and patient preference rather than mutation status alone. Younger patients with CNS disease may benefit from more aggressive upfront combination therapy, while shared decision-making remains central to navigating the expanded efficacy versus increased toxicity trade-off. Dermatologic toxicities associated with amivantamab requires proactive management including supportive care regimen, early dose adjustments and close patient monitoring to maintain treatment continuity. Providing the best available upfront therapy in metastatic EGFR-mutated NSCLC is critical, as sequencing options become more limited at progression. Join us for an insightful discussion on the latest treatment algorithms, the importance of personalized care, and the evolving landscape of NSCLC management.   Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Apple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966   Follow us on social media: ⁠X/Twitter: https://twitter.com/oncbrothers ⁠Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/   Don't forget to subscribe for more episodes featuring conference highlights and challenging cases in oncology! #EGFRMutated, #LungCancer, #ThoracicOncology, #PersonalizedMedicine, #OncologyBrothers

Full Text of Readings The Solemnity of the Most Holy Body and Blood of Christ Lectionary: 167 The Saint of the day is Blessed Franz Jägerstätter Blessed Franz Jägerstätter, an Austrian farmer executed for refusing to fight for Nazi Germany, is pictured in an undated photo. (CNS photo)  Saint of the Day for June 7 (May 20, 1907 – August 9, 1943) Blessed Franz Jägerstätter's Story Called to fight for his country as a Nazi soldier, Franz Jägerstätter eventually refused, and this husband and father of three daughters—Rosalie, Marie and Aloisia—was executed because of it. Born in St. Radegund in Upper Austria, Franz Jägerstätter lost his father during World War I and was adopted after Heinrich Jaegerstaetter married Rosalia Huber. As a young man, he loved to ride his motorcycle and was the natural leader of a gang whose members were arrested in 1934 for brawling. For three years he worked in the mines in another city and then returned to St. Radegund, where he became a farmer, married Franziska and lived his faith with quiet but intense conviction. In 1938, he publicly opposed the German Anschluss–annexation–of Austria. The next year he was drafted into the Austrian army, trained for seven months and then received a deferment. In 1940, Franz was called up again but allowed to return home at the request of the town's mayor. He was in active service between October 1940 and April 1941, but was again deferred. His pastor, other priests, and the bishop of Linz urged him not to refuse to serve if drafted. In February 1943, Franz was called up again and reported to army officials in Enns, Austria. When he refused to take the oath of loyalty to Hitler, he was imprisoned in Linz. Later he volunteered to serve in the medical corps but was not assigned there. During Holy Week Blessed Franz Jägerstätter wrote to his wife: “Easter is coming and, if it should be God's will that we can never again in this world celebrate Easter together in our intimate family circle, we can still look ahead in the happy confidence that, when the eternal Easter morning dawns, no one in our family circle shall be missing—so we can then be permitted to rejoice together forever.” He was transferred in May to a prison in Berlin. Challenged by his attorney that other Catholics were serving in the army, Franz responded, “I can only act on my own conscience. I do not judge anyone. I can only judge myself.” He continued, “I have considered my family. I have prayed and put myself and my family in God's hands. I know that, if I do what I think God wants me to do, he will take care of my family.” On August 8, 1943, Franz wrote to Fransizka: “Dear wife and mother, I thank you once more from my heart for everything that you have done for me in my lifetime, for all the sacrifices that you have borne for me. I beg you to forgive me if I have hurt or offended you, just as I have forgiven everything…My heartfelt greetings for my dear children. I will surely beg the dear God, if I am permitted to enter heaven soon, that he will set aside a little place in heaven for all of you.” Franz Jägerstätter was beheaded and cremated the following day. In 1946, his ashes were reburied in St. Radegund near a memorial inscribed with his name and the names of almost 60 village men who died during their military service. He was beatified in Linz on October 26, 2007. His “spiritual testament” is now in Rome's St. Bartholomew Church as part of a shrine to 20th-century martyrs for their faith. Blessed Franz's liturgical feast is celebrated on August 9. Want to learn more about Blessed Franz Jägerstätter? Click here! Facebook Twitter Pinterest Email Sign Up for Our Daily Newsletter Includes Saint of the Day, Minute Meditations, and Pause + Pray. Saint of the Day, Copyright Franciscan Media

Contributor: Aaron Lessen, MD Educational Pearls:  Back pain is a common presenting complaint in the emergency department. Challenges arise when tailoring care to elderly populations using standard medical therapy: Muscle relaxants carry the risk of CNS depression or anticholinergic effects such as urinary retention and confusion. Pain medications such as opiates have side effects including constipation, respiratory depression, and hypotension. NSAIDs carry a risk of GI bleeding and worsening kidney function with chronic use. A randomized clinical trial assessing the effects of acupuncture on low back pain took 800 adults aged 65 and older with chronic low back pain and placed them into one of three treatment arms: Usual medical care Standard acupuncture consisting of 8–15 treatment sessions over 12 weeks, plus usual medical care Standard acupuncture consisting of 8–15 treatment sessions over 12 weeks, plus 4-6 maintenance sessions during the next 12 weeks, plus usual medical care Using the Roland-Morris Disability Questionnaire (RMDQ) score, they assessed disability at 6 months and 12 months. The study found that those who had undergone treatment with acupuncture had significantly greater improvements in disability related to low back pain compared to the group that was only treated with usual medical care. Acupuncture is not used in the ER, but could represent a relatively safe adjunctive therapy for patients who are not responding to standard medical therapy alone.   References:  American College of Surgeons Committee on Trauma. Best practices guidelines: geriatric trauma management. American College of Surgeons; 2023. Accessed May 27, 2026. https://www.facs.org/media/ubyj2ubl/best-practices-guidelines-geriatric-trauma.pdf DeBar LL, Wellman RD, Justice M, et al. Acupuncture for chronic low back pain in older adults: a randomized clinical trial. JAMA Netw Open. 2025;8(9):e2531348. doi:10.1001/jamanetworkopen.2025.31348 Summarized by Ashley Lyons, OMS3 | Edited by Ashley Lyons & Ahmed Abdel-Hafiz, NREMT-P

We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Jeff Jonas, M.D., CEO of Tortugas Neuroscience, talks about the company's April 2026 launch and how in-licensed development assets were chosen. Jeff explains his strategy of chasing fast proof of safety and efficacy in humans, not animals, and talks about what product differentiation looks like in brain disorders, from adjusting indication targets to conducting head-to-head trials. He also reflects on the opportunity with psychedelics, RFK Jr.'s quest to curb SSRI prescriptions, the payer landscape in CNS disorders, and more. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.  Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

A free guide to FSM training is available there for licensed practitioners. https://frequencyspecific.com/how-to-choose-your-fsm-core-training Hosts: Carolyn McMakin, MA, DC &  Kim Pittis, LCSP, (PHYS), MT 00:00 Episode Preview 00:55 FSM Podcast Intro 01:22 Momentum and Growth 03:25 Student Outreach Plans 05:35 Surgery Scar Pain Case 08:31 Vagus Nerve Protocol 11:17 Treatment Time and Pathways 13:35 Mindset and Buy-In 17:31 Device Is Not Magic 19:46 Treat Causes Not Muscles 24:57 40 89 Precautions 28:49 Pain Processing and CNS 30:53 Objective Assessment Matters 32:08 Range of Motion Proof 32:57 Short Term vs Long Term Goals 33:32 Progress Reset Talk 35:07 Weak vs Inhibited Muscles 37:15 Scar Tissue and Inhibition 39:00 Reformer Joyful Retraining 41:20 Adenovirus Cold Protocols 45:06 Compression Fractures and Appetite 47:57 Bone Healing Nutrients 54:17 Teamwork and Wrap Up 56:20 Resources and Case Webinars 57:33 Take It Apart Method 58:39 Closing and Disclaimer Dr. Carol and Kim Pittis discuss the expansion of Frequency Specific Microcurrent (FSM) training into new remote course formats, student portals for chiropractic colleges, and upcoming UK seminars, emphasizing gaps in standard chiropractic education (hypermobility, vagus nerve, POTS). They share a detailed case of a post-surgical patient with severe abdominal pain, mesh, extensive scarring, nausea, and restless legs whose pain dropped to zero after a long FSM session focused on vagus-related scarring, secretions, and trauma/central sensitization (including 40/89), highlighting that the device isn't "magic" but depends on assessment and correct targets. They stress the importance of patient buy-in, objective measures, and deeper diagnosis (muscles often inhibited, not weak), including examples of scar-related nerve/artery inhibition. They also answer questions on using FSM for common cold protocols and addressing appetite loss with spinal compression fractures via vagus/sympathetic considerations plus vitamin D and bone support. #FrequencySpecificMicrocurrent #FSM #VagusNerve #ScarTissue #ChronicPain #PainManagement #Microcurrent #Fascia #Hypermobility #EhlersDanlos #POTS #Inhibition #MuscleInhibition #Rehab #Physiotherapy #Chiropractic #FunctionalMedicine #IntegrativeMedicine #PainRelief #NervePain #CentralSensitization #CompressionFracture #Adhesions #ContinuingEducation #FrequencySpecificSeminars  

Dr. Hoffman continues his conversation with Dr. Corey Schuler, PhD(c), FNP, DC, CNS, and director of medical affairs at Allergy Research Group.

Dr. Corey Schuler, PhD(c), FNP, DC, CNS, and director of medical affairs at Allergy Research Group, details his paper “Energy Allocation Resilience and Endocrine Integration” in the International Journal of Molecular Sciences. He introduces the Energy Allocation System (EAS), which emphasizes how the body allocates energy—not just produces it—and links many symptoms to impaired bioenergetics and resilience. They discuss mitochondria as energy generators and cellular signaling hubs, the integrated stress response and endocrine coordination (HPA axis, thyroid, gonads), and mitohormesis/eustress (exercise, fasting, heat/cold, circadian “zeitgebers”). Schuler explains nuanced testing for fatigue (diurnal cortisol, CGM patterns, thyroid markers including T3/reverse T3) and a case of a perimenopausal woman where oral contraceptives and cortisol dysregulation affected glucose patterns. They cover mitochondrial support (removing obstacles like pollutants/antibiotics, triglycerides, carnitine, dietary fats, micronutrients) and pacing/sequencing lifestyle interventions.

Recorded last week at Fierce Biotech Week in Boston, this episode of “The Top Line” features a conversation with Kristen Fortney, Ph.D., co-founder and CEO of BioAge Labs. In a conversation with Ayla Ellison, editor-in-chief of Fierce Healthcare and Life Sciences, Fortney discusses the company’s decade-long effort to use human aging data to identify drug targets tied to longevity and age-related disease. She also breaks down BioAge’s oral NLRP3 inhibitor, BGE-102, which the company believes could have applications across cardiovascular, ocular and CNS diseases by targeting inflammation linked to aging biology. The conversation also explores why pharma companies are paying closer attention to aging and exercise biology, how GLP-1 drugs are reshaping conversations around prevention and what the future of aging-related medicine could look like. To learn more about the topics in this episode: BioAge CEO has big plans for 'multi-disease impact' of NLRP3 drug across cardio, ocular and CNS Novartis, BioAge take on age-related diseases in $550M pact What can we learn from 2024’s biotech IPOs? See omnystudio.com/listener for privacy information.

Does GABA Actually Help With Sleep? What the Research Says for Brain Injury Recovery Someone in our community recently asked me about GABA for sleep. They’d seen it recommended online, understood that sleep was critical for their recovery, and wanted to know whether the supplement was worth exploring or just noise. It’s a genuinely good question. And it deserves a proper answer. In this post, I’m going to walk you through what GABA is, what the clinical research actually shows about its effect on sleep, why the blood-brain barrier debate matters (and why it might not derail the whole argument), and what the evidence says about the relationship between sleep and brain recovery. By the end, you’ll have enough to have an informed conversation with your medical team. I’m not a doctor. I’m a three-time haemorrhagic stroke survivor who has spent years researching the science of brain recovery and interviewing hundreds of clinicians and survivors on the Recovery After Stroke podcast. What I offer is a careful read of the evidence, not a clinical prescription. What Is GABA and Why Does It Matter for Sleep? GABA (gamma-aminobutyric acid) is the brain’s primary inhibitory neurotransmitter. If your nervous system were a car, GABA is the brake pedal. It reduces neuronal excitability, quiets cortical arousal, suppresses the brain’s primary arousal centre (the locus coeruleus), and modulates the HPA axis, the stress-response system that drives cortisol. Most sedative medications work by amplifying GABA activity. Benzodiazepines, for instance, bind to GABA-A receptors to increase chloride channel opening, producing their calming effect. GABA isn’t doing something unusual here – it’s doing something fundamental. The question with supplemental oral GABA is more specific: Does taking GABA as a capsule or powder actually produce meaningful neurological effects? What Does the Research Show? Finding 1 — Oral GABA Reduces Sleep Latency (and EEG Can Measure It) A 2015 clinical trial published in the Journal of Nutritional Science and Vitaminology by Yamatsu and colleagues used EEG measurement, actual brainwave monitoring, rather than self-reported sleep questionnaires. One hundred milligrams of oral GABA shortened sleep latency (time to fall asleep) by 5.3 minutes compared to placebo. That might sound modest. But for someone lying awake for 30–40 minutes each night, it’s a meaningful shift. Crucially, this was objective neurophysiological data, not a survey response. (PMID: 26052150) Finding 2 — A 90-Day RCT Showed Improved Sleep Efficiency and Mood A 2024 randomised double-blind placebo-controlled trial published in the Journal of Dietary Supplements (Guimarães et al.) gave 200 mg of GABA daily for 90 days to sedentary overweight women also undergoing an exercise program. The GABA group showed significantly improved Pittsburgh Sleep Quality Index (PSQI) scores, significantly reduced depression scores, and improved heart rate variability, a marker of parasympathetic nervous system activity. The HRV finding is particularly interesting. It suggests GABA may be doing something broader than simply reducing sleep latency – it appears to support the overall physiological state that makes rest restorative. (PMID: 38321713) Finding 3 — But a High-Dose RCT Found No Effect Here’s where intellectual honesty matters. A 2023 Dutch RCT (de Bie et al.) published in the American Journal of Clinical Nutrition gave participants 500 mg of GABA three times daily, 1,500 mg/day total, and found no significant effect on self-reported sleep quality. Fasting plasma GABA wasn’t significantly elevated either, raising real bioavailability questions at that dose. This isn’t a reason to dismiss GABA entirely. It is a reason to pay attention to the dose. The evidence base supports 100–300 mg, not 1,500 mg. Higher is not better, and the non-linear dose response is clinically important. (PMID: 37495019) The Blood-Brain Barrier Debate — and Why the Gut May Be the Point The most common objection to oral GABA supplementation is this: GABA is a zwitterion at physiological pH, meaning it has low lipophilicity and poor predicted ability to cross the blood-brain barrier via passive diffusion. So if it can’t get into the brain directly, how does it produce neurological effects? The emerging explanation involves the gut-brain axis. The enteric nervous system, your gut’s own neural network, has GABA receptors. When oral GABA activates these enteric receptors, it can signal the brain via vagal afferents without needing to cross the BBB at all. Think of it as a side door rather than the front entrance. Supporting this: a 2024 RCT (Li et al.) found that a probiotic strain engineered to increase gut GABA production significantly improved objective sleep duration as measured by wearable devices, alongside reduced cortisol and suppressed HPA axis activity. The mechanism wasn’t direct CNS access – it was gut-brain signalling. (PMID: 39385735) The BBB debate doesn’t negate the clinical effect. It changes how we understand the mechanism. Why Sleep Is Not Optional in Brain Recovery This is the part that I think gets underweighted in recovery conversations — and the research is unambiguous. A 2026 large retrospective cohort study (Muhtar et al., Sleep Medicine) matched over 35,000 stroke patients and found that post-stroke insomnia was associated with a 29% higher risk of post-stroke cognitive impairment and a 30% higher risk of all-cause dementia. The association with Alzheimer’s disease was also significant. (PMID: 41924789) A 2024 observational study from Monash University and Alfred Health (Smith et al.) found that in stroke rehabilitation patients, poor sleep quality was significantly associated with higher fatigue severity and lower salivary BDNF gene expression. BDNF (brain-derived neurotrophic factor) is one of the primary molecular drivers of neuroplasticity. Less BDNF means a less receptive environment for the neurological rewiring that rehab is trying to build. (PMID: 38802847) And then there’s the glymphatic system: the brain’s waste-clearance mechanism that is most active during deep sleep. Poor sleep means reduced clearance of metabolic byproducts, including proteins associated with neurodegeneration. This is not a theoretical risk. It is an active, ongoing process. Sleep is not passive recovery. It is one of the primary mechanisms of recovery. What to Do With This Information Here are three practical steps if you’re exploring GABA for sleep: 1. Measure your sleep baseline first. Use the Pittsburgh Sleep Quality Index (freely available online) before you make any changes. Understanding whether you’re struggling with latency, duration, or quality will determine what you actually need to address. 2. If you trial GABA, choose the right form and dose. Look for PharmaGABA — naturally fermented GABA, derived from Lactobacillus hilgardii, which has the strongest clinical evidence base. A dose of 100–300 mg taken 30–60 minutes before bed is consistent with the positive studies. Avoid very high doses; the null result at 1,500 mg/day is important context. Important drug interaction note: If you are taking benzodiazepines, anticonvulsants (gabapentin, pregabalin, valproate), or any other GABAergic medication, discuss GABA supplementation with your prescriber before adding it. The additive sedative effect is a real risk. The same applies if you drink alcohol regularly. 3. Don’t skip the foundation. Sleep hygiene interventions, consistent sleep and wake times, a dark and cool room, and no screens in the 60 minutes before bed, are consistently among the highest-leverage sleep interventions in the literature. GABA may provide a genuine incremental benefit. But it cannot compensate for a fundamentally disrupted sleep environment. The Bottom Line The evidence for GABA and sleep is more substantive than I expected when I started researching it. The EEG data is real. The 90-day RCT showed meaningful clinical outcomes. The gut-brain axis mechanism is biologically plausible and now has direct RCT support. And the consequences of poor sleep in neurological recovery are not trivial – they are quantifiable, significant, and, to a degree, addressable. GABA is not a guaranteed fix. Individual responses vary. The research is not yet definitive at the level of large multi-centre trials in neurological populations. But as one tool in a comprehensive approach to sleep quality alongside good sleep hygiene, appropriate medical support, and consistent rehabilitation, the case for cautious exploration is reasonable. The next step is a conversation with your neurologist, GP, or rehab physician. Take the research with you if it’s useful. Research References All studies cited in this post are retrievable via PubMed: Yamatsu et al. — GABA sleep latency EEG clinical trial (2015) — PMID: 26052150 Guimarães et al. — GABA 200mg RCT, sleep efficiency + mood (2024) — PMID: 38321713 de Bie et al. — GABA high-dose RCT, null sleep result (2023) — PMID: 37495019 Li et al. — Gut-brain GABA axis and sleep RCT (2024) — PMID: 39385735 Muhtar et al. — Post-stroke insomnia and cognitive decline cohort (2026) — PMID: 41924789 Smith et al. — Sleep, BDNF, and fatigue in stroke rehabilitation (2024) — PMID: 38802847 This post is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before making changes to your supplementation or treatment plan. If you or someone you care about is recovering from a stroke, brain injury, or any neurological condition, the Recovery After Stroke podcast and this blog exist for you. Subscribe on YouTube @BillGasiamis, or visit Recovery After Stroke to find episodes, resources, and community. The post GABA, Sleep, and Brain Health – Neurological Recovery appeared first on Recovery After Stroke.

Creatine and Microbiomes A new 2026 Cell Metabolism study explores a compelling and increasingly central idea in modern biology: the gut/brain/immune/metabolism axis is not just associative, it is mechanistic. Specifically, Dr. Lu and colleagues investigate how the gut microbiota can directly influence depressive behavior by reshaping systemic and neural metabolism. This is another in a long running list of papers describing the amazing work that bacterial commensal microbes do for us. In this case, our minds and moods. "Although peripheral-brain crosstalk regulates energy metabolism, its role in depression remains unclear. Here, we used metabolic profiling to reveal elevated fecal creatine alongside reduced plasma and cerebrospinal fluid creatine in both patients with depression and mouse depression models. Exogenous creatine produced antidepressant-like effects mediated by gut microbiota. Bifidobacterium pseudolongum was identified as a significantly reduced gut bacterial species in depression, correlating with impaired creatine absorption. Subsequent supplementation with Bifidobacterium enhanced the antidepressant effects of creatine. Mechanistically, B. pseudolongum-derived acetate promoted the creatine transporter (Slc6a8) expression in intestinal epithelial cells via histone acetylation. The Slc6a8 mediated the antidepressant-like effects of creatine. Neuronal creatine deficiency influenced energetic metabolism and neurophysiological function. In patients with depression taking antidepressants, co-administration of creatine and Bifidobacterium increased plasma creatine levels and reduced depression scores. These findings identify the Bifidobacterium-creatine combination as a promising antidepressant strategy and highlight the critical role of gut-brain energy metabolism in depression." "The brain, as an energy-intensive organ, relies on precise metabolic regulation to maintain synaptic plasticity, neurotransmitter synthesis, and stress response systems. Accumulating evidence implicates energy metabolism dysregulation as a hallmark of depression. Neuroimaging studies using positron emission tomography (PET) have identified marked glucose hypometabolism in the medial prefrontal cortex (mPFC) of patients with depression. Cerebral mitochondrial dysfunction and ATP imbalance have been mechanistically linked to depression progression. Notably, emerging studies emphasize the bidirectional interplay between peripheral metabolic signals and central energy regulation, which is fundamental to neural metabolism. Clinical observations such as fatigue, appetite dysregulation, and unexplained weight fluctuations in patients with depression further suggest systemic metabolic disturbances spanning peripheral organs and the CNS.." (Lu et. al. 2026) This is next-level medicine. Mental health can no longer be framed as a disorder of genetics, experience, or circumstance alone. This work opens a clearer window, showing how the microbiome participates as an active partner, shaping brain function through the metabolites it helps produce and deliver. Compounds like creatine are no longer just peripheral players. They become signals, fuel, structure, and information, bridging gut and brain, metabolism and behavior.... and more Enjoy, Dr. M

Listen Online: About this episode: Together, The First Lady of Nutrition and James Templeton, CEO of UNI KEY Health, author of I Used to Have Cancer, and a 40+ year stage 4 cancer survivor, tackle one of the most debated questions in health: What is the best diet to beat cancer?Drawing from his personal journey and decades of experience, James shares why he believes diet is the most critical factor in healing—and why removing sugar (including excess carbohydrates) is absolutely essential. He explores the pros and cons of popular approaches like vegan, paleo, keto, and macrobiotic diets, and explains why he ultimately leans toward an anti-fungal, anti-candida style of eating—focused on clean protein, healthy fats, and minimal sugar. Listeners will also hear his take on fermented foods like sauerkraut and kimchi, the role of fruit, and why grains and dairy can be problematic for some individuals.James also reflects on the diet that helped him recover—and why it wasn't the same diet he used to maintain long-term health. This conversation goes beyond theory, offering practical insights on what to eat, what to avoid, and how to think differently about food when it comes to prevention and healing.To learn more about James’ non-profit foundation, check out The Templeton Wellness Foundation at: www.templetonwellness.com . The post The Cancer Diet Debate: What Really Works? With James Templeton first appeared on Ann Louise Gittleman, PhD, CNS.

Why some lifters go straight to failure with no grinder reps—explained through muscle fiber types, CNS fatigue, and training science. Learn how to push past early failure and unlock more effective reps for hypertrophy. Practical tips to improve effort, bar speed awareness, and get more out of every set. 0:00 Muscle Minds Introduction 1:13 Van Life and Simple Living 3:44 Training Intensity and Bar Speed 7:29 Muscle Fiber Types and Fatigue 27:21 Visualization and Training Techniques 33:50 Psychological Aspects of Training 43:04 Pain Tolerance and Gender Differences 1:02:09 Conclusion and Next Episode Teaser

Book a free consultation call with Robert Sikes on breaking through your Keto or low carb plateau here: https://www.ketobodybuilding.com/callFitness influencers are lying to you about how to build big muscles fast. High intensity training is not the shortcut you think it is. In episode 879 of the Savage Perspective Podcast, host Robert Sikes and guest Dr. Nash Jocic break down high intensity vs high volume training for muscle growth, especially for natural lifters. They cover weekly training splits, recovery, tendons, CNS fatigue, reps and rest times, and why meat and eggs can beat high carbohydrate diets for strength, leanness, and long-term progress.Follow Dr. Jocic on IG: https://www.instagram.com/nash_jocic/Subscribe to his YouTube Channel: https://www.youtube.com/nashjocic888/joinGet Keto Brick: https://www.ketobrick.com/Subscribe to the podcast: https://open.spotify.com/show/42cjJssghqD01bdWBxRYEg?si=1XYKmPXmR4eKw2O9gGCEuQ

What if one of the biggest health threats on Earth… is something you can't see, taste, or even fully measure yet? In this urgent solo episode, Darin breaks down the rapidly escalating crisis of microplastics and nanoplastics infiltrating our bodies, water systems, and environment. What was once dismissed is now being acknowledged at the highest levels, with government agencies scrambling to understand and contain the damage. From plastics crossing the blood-brain barrier to disrupting hormones and carrying toxic chemicals deep into human tissue, this episode exposes the hidden cost of modern convenience, and more importantly, gives you practical, immediate actions you can take to protect yourself and your family. What You'll Learn Why microplastics are now considered a global health emergency How plastics accumulate in your body and environment The shocking truth about nanoplastics crossing the blood-brain barrier How plastics act as endocrine disruptors affecting hormones The connection between plastics and inflammation, fertility, and disease Why tap water and bottled water are both major exposure sources The role of PFAS ("forever chemicals") in long-term health damage How to filter and detox microplastics from your body Emerging science on breaking down plastics using bacteria and plants Simple, actionable steps to dramatically reduce your exposure Chapters 00:00:00 – Welcome to SuperLife 00:02:12 – Opening: committing to a clean, conscious life 00:02:27 – Fatal conveniences and why awareness matters 00:02:46 – Government officially flags microplastics as a crisis 00:03:04 – $100M+ initiatives to understand plastic contamination 00:03:38 – Microplastics in drinking water and daily exposure 00:04:20 – Plastics found in babies and human brains 00:04:45 – Why we still don't understand the full damage 00:05:08 – Nanoplastics crossing the blood-brain barrier 00:05:33 – Plastics as endocrine disruptors 00:06:02 – Hormonal imbalance, inflammation, and toxicity 00:06:30 – PFAS and the "forever chemical" crisis 00:06:59 – The #1 rule: stop using single-use plastic bottles 00:07:27 – Hidden dangers of "BPA-free" plastics 00:07:58 – Why you can no longer trust tap water 00:08:30 – The importance of high-quality water filtration 00:09:11 – Reverse osmosis systems and best practices 00:10:17 – Detox strategies: sweating and sauna use 00:10:59 – Fiber and plant-based diets binding toxins 00:11:24 – Medicinal mushrooms and beta glucans 00:11:52 – Microbes that break down plastic polymers 00:12:32 – Plant-based flocculants (okra, fenugreek) removing plastics 00:13:20 – Bio-sponges and advanced filtration innovations 00:13:46 – Magnetic separation technology 00:14:27 – Microplastics from clothing and laundry systems 00:15:16 – AI-assisted filtration and regulatory changes 00:15:55 – Light-activated breakdown of plastics 00:16:03 – Boiling water to remove up to 90% of microplastics 00:16:33 – Practical emergency water filtration methods 00:16:59 – Creating a low-toxicity lifestyle at home 00:17:20 – Final message: take control and protect your health 00:17:32 – Outro     Thank You to Our Sponsors Tru Niagen – Boost NAD+ levels for cellular health and longevity. Get 20% off with code DARIN20 at truniagen.com. Shakeology – Shakeology-All in One Nutrition: Get 15% off with code SUPERLIFE at Shakeology.com.     Join the SuperLife Patreon: This is where Darin now shares the deeper work: - weekly voice notes - ingredient trackers - wellness challenges - extended conversations - community accountability - sovereignty practices Join now for only $7.49/month at https://patreon.com/darinolien     Connect with Darin Olien: Website: darinolien.com Instagram: @darinolien Book: Fatal Conveniences Platform & Products: superlife.com New Show: Roadmap to Happiness     Key Takeaway: "We are living in a world where convenience has quietly introduced toxins into nearly every aspect of our lives, but you are not powerless. The moment you become aware, you can take action. And the small choices you make every day: what you drink from, how you filter your water, what you put into your body, can dramatically shift your long-term health and your family's future."     Bibliography/Sources: The News Hook — EPA CCL6 & STOMP Initiative Chemical & Engineering News. (2026, April 3). US government targets microplastics for research and potential drinking-water regulation. American Chemical Society. https://cen.acs.org Environmental Protection Agency. (2026, April 2). EPA takes bold action to ensure drinking water is safe from microplastics, pharmaceuticals, and potential hidden contaminants [Press release]. https://www.epa.gov/newsreleases Environmental Protection Agency & Department of Health and Human Services. (2026, April 2). EPA, HHS announce historic actions to protect Americans from microplastics and safeguard drinking water [Press release]. https://www.epa.gov/newsreleases Inside Climate News. (2026, April 3). EPA flags microplastics as 'priority' water contaminants, but the move doesn't guarantee regulation. https://insideclimatenews.org National Public Radio. (2026, April 2). EPA flags microplastics, pharmaceuticals as contaminants in drinking water. https://www.npr.org STAT News. (2026, April 2). EPA to put microplastics on study list of contaminants in drinking water. https://www.statnews.com The New Lede. (2026, April 2). EPA flags microplastics as 'priority' contaminants in drinking water. https://thenewlede.org U.S. Government. (2026). Public comment docket: EPA-HQ-OW-2022-0946. https://www.regulations.gov The Science — Brain Invasion & Cellular Damage ACS Environment & Health. (2025). Neurotoxicity of micro- and nanoplastics: A comprehensive review of CNS impacts. American Chemical Society. https://pubs.acs.org Journal of Nanobiotechnology. (2025). Maternal nanoplastic exposure led to impaired neuronal development in the fetal cortex. Springer Nature. PubMed Central. (2023). Micro-/nanoplastics breach the blood-brain barrier: Biomolecular corona's role revealed. National Institutes of Health. https://pmc.ncbi.nlm.nih.gov PubMed Central. (2024). A review on micro- and nanoplastics in humans: Translocation of barriers and potential health effects. National Institutes of Health. https://pubmed.ncbi.nlm.nih.gov PubMed Central. (2025). Overall effects of microplastics on brain. National Institutes of Health. https://pmc.ncbi.nlm.nih.gov ScienceDirect. (2025). Mechanisms of micro- and nanoplastics on blood-brain barrier crossing and neurotoxicity. Elsevier. https://www.sciencedirect.com The Science — Endocrine Disruption & Gut Health eClinicalMedicine. (2026). Phthalates attributed to nearly 2 million preterm births globally. The Lancet. Frontiers in Cellular and Infection Microbiology. (2024). Microplastics, human health, and the gut microbiome. Frontiers. https://www.frontiersin.org Frontiers in Endocrinology. (2023). A review of the endocrine disrupting effects of micro and nano plastic in mammals. Frontiers. International Journal of Molecular Sciences. (2025). Micro- and nanoplastics as disruptors of the endocrine system. MDPI. https://www.mdpi.com PubMed Central. (2025). Microplastics, endocrine disruptors, and oxidative stress. National Institutes of Health. Solutions — Filtration & Global Removal Technologies ACS Applied and Environmental Microbiology. (2024). Eco-microbiology: Discovering biochemical enhancers of PET biodegradation by Piscinibacter sakaiensis. American Chemical Society. ACS Omega. (2025). Thermostability and activity improvements of PETase from Ideonella sakaiensis. American Chemical Society. Environmental Science & Technology Letters. (2024). Drinking boiled tap water reduces human intake of nanoplastics and microplastics. American Chemical Society. https://doi.org/10.1021/acs.estlett.4c00081 Srinivasan, R., et al. (2025). Fenugreek and okra polymers as treatment agents for the removal of microplastics from water sources. ACS Omega. https://doi.org/10.1021/acsomega.4c07476 Yoshida, S., et al. (2016). A bacterium that degrades and assimilates poly(ethylene terephthalate). Science.